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Abstract 
Arginine methylation is a prevalent post-translational modification that is found on 
many nuclear and cytoplasmic proteins, and has been implicated in the regulation of gene 
expression. CARM1 is a member of the protein arginine methyltransferase (PRMT) family of 
proteins, and is a key protein responsible for arginine methylation of a subset of proteins 
involved in transcription. In this thesis I examine some of the mechanisms through which 
CARM1 contributes to global transcriptional regulation. 
Using a ChIP-DSL approach, we show that the p/CIP/CARM1 complex is recruited 
to 204 proximal promoters following 17β-estradiol (E2) treatment in MCF-7 cells. Many of 
the target genes have been previously implicated in signaling pathways related to 
oncogenesis. JAK2, a member of the Jak/Stat signaling cascade, is one of the direct E2-
dependent targets of the p/CIP/CARM1 complex. Following E2-treatment, histone 
modifications at the JAK2 promoter are reflective of a transcriptionally permissive gene, and 
we observed modest increases in RNA and protein expression. Notably, E2-induced 
expression of Jak2 was diminished when p/CIP or CARM1 were depleted, suggesting that 
the p/CIP/CARM1 complex is required for the observed transcriptional response. 
Collectively, these results suggest that E2-dependent recruitment of the p/CIP/CARM1 
complex causes JAK2 to become ‘poised’ for transcription, a finding that may be extendable 
to other target genes and signalling pathways. Furthermore, bioinformatic examination of 
p/CIP/CARM1 target promoters suggests that transcription factor crosstalk is the favored 
mechanism of E2-dependent p/CIP/CARM1 complex recruitment.  
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Using ChIP-Seq, we identified genomic regions to which CARM1 is recruited. 
Subsequent characterization of binding events suggest a role for CARM1 in transcriptional 
elongation, and implicate the transcription factor PAX1 as a novel mechanism through which 
CARM1 can be recruited to the genome. Identification of CARM1-dependent differentially 
expressed genes revealed that direct recruitment of CARM1 is not essential for the majority 
of its transcriptional effects in MEFs. However, CARM1 does play a critical role in cellular 
growth and proliferation, and in the absence of CARM1, the expression of many cell cycle 
regulators is dramatically affected.  
Collectively, this work provides insight into some of the mechanisms through which 
CARM1 modulates transcription, and highlights its importance in diverse cellular processes. 
 
 
 
Keywords 
Transcription, transcriptional regulation, chromatin, histone modifications, chromatin 
immunoprecipitation (ChIP), cancer, estrogen, coregulators, steroid receptor coactivators, 
arginine methylation, p/CIP, CARM1 
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  Chapter 1
 General Introduction 1
1.1 Gene Expression 
Gene expression is a general term applied to the process in which the genetic 
information encoded within DNA becomes processed into a functionally useful form(s). 
The first step in this process is transcription, wherein RNA Polymerase (RNAP) reads the 
DNA template strand and produces a primary RNA transcript. The primary transcript is 
then processed and/or spliced, giving rise to mature mRNA, in addition to the more 
recently discovered non-coding RNA (ncRNA)  [1]. Transport of mRNA from the 
nucleus to the cytoplasm is essential for protein production, termed translation, which 
takes place in ribosomes. An overview of the levels at which gene expression can be 
regulated is shown in Figure 1-1, and can conceptually be broken down into four 
component sections: transcriptional regulation, post-transcriptional regulation, 
translational regulation, and post-translational regulation.  
While each cell within an organism is encoded with the same genetic information, 
there are vast differences in the size, shape, function, and lifespan of each cell type. 
These differences can be largely accounted for by distinct cellular gene expression 
profiles, with genes being expressed in a tissue/cell-specific and time-dependent manner. 
Development in particular is characterized by major changes in gene expression 
corresponding to changes in cell determination, and resulting in the differentiation of 
cells into distinct lineages. Many cellular processes are common to all cell types, and so 
all cells will express certain common genes and proteins. It has been determined that a 
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given human cell expresses between 30-60% of approximately 25,000 genes at any given 
time  [1,2]. Notably, aberrant regulation of transcription is often involved in disease 
states, including cancer.  
 
1.2 Transcriptional Regulation 
The work presented within this thesis is primarily concerned with the regulation 
of gene expression at the level of transcription. A complex association between cis-acting 
regulatory DNA sequences, trans-acting DNA-binding proteins, and chromatin 
compaction modulates transcriptional regulation  [3,4]. Regulatory DNA sequences, also 
known as response elements, generally represent sites within the genome at which protein 
binding can occur. These elements can occur both proximal to and/or distal from the gene 
to be transcribed. Proximal regulatory sequences occur within the promoter region, 
consisting of the core promoter and adjacent regulatory elements, while distal regulatory 
sequences can exist up to 1Mbp from the transcription start site (TSS). Distal regulatory 
elements can include enhancers, silencers, insulators, and locus control regions  [4]. 
Trans-acting DNA-binding proteins bind to cis-acting regulatory sequences and function 
to either activate or repress transcription. 
Transcription classically consists of three stages: initiation, elongation, and termination  
[1]. Each stage involves multiple factors and a specific sequence of events in order to 
proceed, with an RNAP common to all stages. There are three different RNA 
Polymerases in eukaryotes, each responsible for the transcription of a different form of 
RNA. RNAPI synthesizes ribosomal RNA (rRNA); RNAPII is responsible for the   
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Figure 1-1 Regulation of gene expression 
Overview of gene expression, highlighting the various points at which regulatory control is 
exerted, as well as the some of the mechanisms in regulation. Figure reproduced from Banks et al. 
2000 [5]. 
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production of messenger RNA (mRNA), as well as several types of noncoding RNAs; 
and RNAPIII generates primarily transfer RNA (tRNA). RNAPII is responsible for the 
production of transcripts from protein-coding genes, and its role in transcription has been 
extensively characterized  [6,7]. 
Prior to initiation, and the addition of the first nucleotide in the mRNA transcript, 
there are many pre-initiation steps that ultimately make transcriptional initiation a critical 
regulatory step in the conversion of DNA to RNA. The key factors required for 
transcription initiation include RNAPII, general and specific transcription factors, 
Mediator, as well as proteins that possess chromatin-modifying and chromatin-
remodeling activities.  RNAPII is the enzyme that synthesizes mRNA from the DNA 
template during transcription. Its recruitment is dependent on a variety of transcription 
factors, and its activity and processivity can be affected by post-translational 
modifications  [3,8]. General transcription factors help localize RNAPII to the core 
promoter of the gene to be transcribed, and participate together with RNAPII as part of 
the transcription initiation complex  [3,4].  
Specific transcription factors can be defined as sequence-specific DNA binding 
proteins that become recruited to regulatory regions, such as the proximal promoter or 
distal enhancer regions of specific populations of genes to be transcribed. Recruitment of 
specific transcription factors often occurs in response to an extrinsic signal, or in a 
developmentally-timed manner.  The specific TFs can interact with the general 
transcriptional machinery described above, and drive activation or repression of 
transcription  [3]. Both general and specific transcription factors can also interact with 
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coregulatory proteins which often act as mediators of their interaction, and modulators of 
transcription factor activity  [3].  
Initially, a pre-initiation complex forms on selected promoters upstream of the 
TSS, involving binding of general transcription factors and RNAPII. Activators and/or 
repressors that will control the rate of transcription can also participate as part of the pre-
initiation complex. Transcriptional initiation progresses through promoter melting, 
clearance, and escape, until an RNAPII elongation complex is formed and the transcript 
becomes extended  [4]. The C-terminal domain of RNAPII is an important regulatory 
component, consisting of multiple heptapeptide repeats, which can be extensively post-
translationally modified  [9]. Phosphorylation of the C-terminal domain of RNAPII is 
critical for activation, and immediately precedes the onset of transcriptional elongation  
[3,10,11]. 
In vivo, the packaging of DNA complicates transcription further, as access to 
promoter and enhancer regulatory elements can be limited by chromatin condensation. 
Chromatin-modifying and chromatin-remodeling proteins are therefore critically 
important during transcriptional initiation, to alter the packaging of DNA such that the 
regions containing genes to be expressed, and their associated regulatory regions, are 
accessible to the general transcriptional machinery. A more detailed examination of the 
role that chromatin plays in transcriptional regulation is the focus of the following 
section. 
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1.3 Chromatin and Regulation of Transcription 
 In order to accommodate the nearly 2m of DNA within a cell’s nucleus, a 
complex system of compaction is employed. Compaction of DNA is facilitated by a 
group of proteins known as histones, and compacted DNA is referred to as chromatin, the 
most basic subunit of which is a nucleosome. Nucleosomes are formed when 
approximately 146bp of DNA is wrapped around an octamer of proteins made up of pairs 
of the core histones (H2A, H2B, H3 and H4). A fifth histone is also involved in 
packaging of chromatin; histone H1 acts as a stabilizer, interacting with linker DNA 
between nucleosomes, and helping to facilitate further coiling into a 30nm fiber  [12]. 
Subsequent looping and compression ultimately result in the final condensed 
chromosome. An overview of this packaging is shown in Figure 1-2. 
Packaging DNA in this manner adds a regulatory component by which gene 
expression can be controlled. Chromatin can be classified as being in one of two states: 
heterochromatin or euchromatin  [1]. Heterochromatin is the term used to describe tightly 
packed DNA, which is relatively inaccessible to transcriptional machinery, and is 
therefore associated with gene silencing. In contrast, euchromatin constitutes more 
loosely packed DNA, which is generally more gene rich, and accessible to regulatory 
factors that can transcribe genes. Changes in DNA condensation, and by extension its 
accessibility, can be a dynamic process, allowing for the expression of specific genes in a 
temporally- or spatially-dependent manner. 
Nucleosome structure adds a further complexity to gene regulation. When DNA is 
wrapped around the core octamer, the structure allows for the protrusion of the amino 
(N)-terminal tails of the core histones. These protruding tails are targets for a variety of   
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Figure 1-2 DNA packaging - levels of chromatin compaction 
DNA is sequentially packaged in cells, such that the double helix is coiled into 
nucleosomes resembling “beads on a string”, and further packaged into higher order 
structures, ultimately resulting in a fully condensed chromosome.  Heterochromatin refers 
to tightly packaged chromatin, repressive to transcription. Euchromatin refers to a more 
open chromatin state, more conducive to gene expression.      
Credit: Darryl Leja/National Human Genome Research Institute
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Figure 1-3 Nucleosome Structure & post-translational modifications of histone tails 
Top: Representative image of nucleosome structure; comprised of an octamer of histone proteins 
around which DNA is wrapped. Evident are the N-terminal histone tails protruding outward from 
the nucleosome. Bottom: Overview of known covalent histone tail modifications. Figure 
reproduced from New York Academy of Science eBriefing 2011 and Xu 2013 [13]. 
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post-translational modifications that can affect gene expression, either by altering the 
chromatin structure directly, or by bringing histone tails [and surrounding DNA] into 
close proximity with regulatory factors thereby facilitating their functional interaction 
(Figue 1-3). 
 
1.3.1 The Language of Covalent Histone Modifications 
 Specific patterns of covalent histone modifications can be predictive of distinct 
biological outcomes; in particular, specific combinations of modifications can serve as a 
signal for transcriptional activation or repression. Allis and colleagues coined the phrase 
‘the histone code’ to describe the observations that chromatin modifications could 
cooperate with, or antagonize, one another to trigger different functional responses  
[14,15]. Histone modifications such as acetylation, phosphorylation, methylation, 
ubiquitination, and/or sumoylation, can alter transcriptional activity by changing the 
compaction of the chromatin, thus altering the accessibility of transcriptional machinery 
to DNA. Alternately, modifications can act as recognition elements for other factors that 
will alter structure and/or regulate transcription  [16,17]. Broadly, three classes of 
proteins can be associated with the histone code: ‘writers’, which deposit the 
modification(s), ‘erasers’ remove the modification(s), and ‘readers’ or ‘effectors’ that 
recognize the modified N-terminal residue(s) and mediate transcriptional consequences.  
Acetylation is the best characterized among the histone post-translational 
modifications, with a connection between histone acetylation and transcription first 
documented in 1964  [18]. Generally, an increase in histone acetylation is predictive of 
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transcriptional activation. Acetylation of histones occurs on lysine residues, and the 
modification effectively neutralizes the positively charged residue, disrupting the ability 
of the histone to interact with negatively charged DNA  [19-21]. Histone Acetyl 
Transferases (HATs) are the enzymes responsible for acetylation of histones  [22,23], 
with Histone Deacetylases (HDACs) acting in the reverse capacity  [24,25], to remove 
the acetyl group(s) and allow the chromatin to return to a more transcriptionally 
repressive heterochromatic state. Acetylated lysines can also act as an interaction surface 
recognized by specific modules found within regulatory proteins such as bromodomains  
[26,27], or tandem PHD (plant homeodomain) fingers  [28,29]. Both of these domains 
recognize acetylated lysines with hydrophobic binding pockets, and facilitate the 
interaction by means of hydrogen bonding  [29]. 
Histone phosphorylation occurs primarily on serine and threonine residues, and 
has been associated with both transcriptional activation and repression. In addition, 
phosphorylation has been implicated in DNA damage repair  [30-32], and in chromosome 
condensation during mitosis and meiosis  [33-35]. In a transcriptional context, the 
addition of the negatively charged phosphate group to the positively charged histone tail 
would be expected to cause decondensation of chromatin. Consistent with this 
expectation, phosphorylation of histone H3 at serines 10 and 28, and at threonine 11 has 
been associated with transcriptional activation, as well as with histone acetylation  [36-
38]. Crosstalk with other modifications is a key component when interpreting histone 
phosphorylation, with specific phosphate groups affecting the ability of nearby residues 
to become acetylated  [36-38] and/or methylated  [39,40].  
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Understanding the functional effects of methylation of lysine and arginine resides 
within histones has proved to be a difficult endeavor. Multiple methyl groups can be 
added to the same residue, complicating the interpretation of transcriptional 
consequences; lysines can be mono-, di-, and tri-methylated, while arginines can be 
mono-, and di-methylated (asymmetrically or symmetrically)  [41,42]. Methylation of 
lysine and arginine residues has been implicated in both activation and repression of 
transcription  [42]. Addition of methyl groups does not alter the charge of lysine or 
arginine residues, and therefore does not drastically affect electrostatic interaction of the 
positive histone tails with the negatively charged DNA. Instead, methylation of lysine or 
arginine has been shown to provide interaction surfaces for effector proteins, which can 
impact the chromatin compaction. Methylation of lysine groups is predominantly 
achieved by a group of enzymes containing a SET domain  [43], using S-adenosyl 
methionine (SAM) as a methyl donor. The process is reversible, with two protein families 
implicated in demethylating lysine residues: Lysine-Specific Demethylases (LSD) that 
belong to the larger collection of amine oxidases  [44], and the Jumonji-C (JmjC)-
domain-containing family of demethylases  [45]. The number of protein domains found 
to interact with methylated lysine continues to grow, and currently includes 
chromodomains, PHD fingers, Tudor domains, WD-40 domains, and MBT domains  
[17,46]. Some of these domains only recognize a specific histone lysine residue, and/or 
residues that have been modified in a particular way, while others are more promiscuous 
in their binding. For example, the Tudor domain of 53BP1 exclusively interacts with 
dimethylated lysine 4 or 9 on histone H3 (H3K4me2, H3K9me2) and dimethylated lysine 
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20 on histone H4 (H4K20me2), while the chromodomains of HP1 and CDY1 recognize 
mono-, di-, and tri-methylated lysine 9 on histone H3 (H3K9)  [46]. 
The Protein Arginine Methyltransferase (PRMT) family is responsible for histone 
arginine methylation, and also uses SAM as a donor. In 2007, Chang et al. suggested that 
Jumonji domain-containing protein 6 (JMJD6) could demethylate histone H3 at arginine 
2 (H3R2) and histone H4 arginine 3 (H4R3)  [47]. However, this finding was not 
reproducible, and it could be argued that a ‘true’ arginine demethylase has yet to be 
identified. However, the modification is not irreversible; peptidylarginine deiminase 
(PADI) enzymes can convert methylated [and unmethylated] arginine residues to 
citrulline  [48,49]. Readers of methylated arginine residues have also been discovered, 
with the PHD motif-containing ADD domain of DNMT3A shown to interact with a 
symmetrically dimethylated arginine residue on histone H4 (H4R3me2s)  [50]. In 
addition, Tudor domains have been found to recognize asymmetrically dimethylated 
arginines. For example, Tudor domain-containing protein 3 (TDRD3)  [51] has been 
shown to interact with the arginine methylated C-terminal domain of RNAPII, and this 
association is important for transcriptional activation by the estrogen receptor (ER) at 
some genes. Understanding of the dynamic regulation of histone lysine and arginine 
methylation and demethylation, the factors involved in the deposition and removal of the 
methyl groups, and the transcriptional and functional roles of these modifications, 
continues to develop. 
 Finally, ubiquitination or sumoylation can also occur on lysine residues. 
Ubiquitination of histones generally allows chromatin decondensation, access for 
transcriptional enzymes, and increased transcription  [52]. Ubiquitination of histones 
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primarily occurs on histone H2A and H2B. Histone H2A ubiquitination has been 
implicated in transcriptional repression  [53], while modification of histone H2B has been 
associated with activation and has been shown to promote other activating histone 
modifications in both yeast and mammalian systems  [54-57]. Addition of small 
ubiquitin-related modifier (SUMO) groups to histones and transcription factors is related 
to gene silencing, as deposition of this modification has been shown to recruit 
transcriptional repressors  [58,59].  
Interpretation of the vast combinations of covalent histone modifications is an 
ongoing and highly active area of research, with the application of high throughput, 
genome-wide technologies such as ChIP-Seq greatly increasing our ability to identify 
patterns of histone modifications. The existence of multiple recognition motifs for 
individual marks, as in the case of lysine methylation in particular, attests to the 
complexity of the ‘code’. Furthermore, the binding affinity of a reader for a specific 
modification can be enhanced or inhibited by adjacent marks, with many chromatin 
regulatory proteins containing more than one ‘reader’ domain  [17]. Ultimately, while 
any single histone tail modification can suggest a particular chromatin state and 
transcriptional consequence, it is the combinatorial makeup of the modifications as a 
whole, and the cross-talk between them that ultimately regulated gene expression. 
 
1.4 Transcription Factors 
 Transcription factor is a general term for any protein directly involved in 
regulating transcriptional initiation. These regulatory proteins typically recognize and 
14 
 
interact with DNA in a sequence-specific manner. DNA-protein interaction can be 
attributed to several known DNA-binding structural motifs. Transcription factors can be 
grouped based on the motif(s) they contain, the most common of which include helix-
turn-helix, zinc finger, leucine zipper, and helix-loop-helix.  
The first DNA binding domain to be identified was the helix-turn-helix  [60]. This 
motif consists of two α helices connected by a short chain of amino acids that comprise 
the turn. The two helices are held at a fixed angle, allowing for the interaction of the C-
terminal helix with the major groove of the DNA  [1,61,62]. This interaction is sequence 
specific, and the variability in amino acid sequence both within the helix-turn-helix 
region, and in the overall protein allow for variability in binding specificity. Helix-turn-
helix-containing transcription factors bind as symmetric dimers to symmetrically 
arranged half-sites within the DNA sequence  [1,63].  
DNA-binding motifs that include zinc ions as structural components are known as 
zinc fingers. A combination of cysteine and histidine residues within the amino acid 
sequence is used to coordinate the zinc ion(s). Zinc finger-containing proteins are 
numerous and are generally grouped based on their structure, with the first type of zinc 
finger protein discovered containing an α helix and two-stranded β sheet held together by 
zinc, coordinated by two cysteine and two histidine residues  [1,62,64]. This type of zinc 
finger can occur in clusters, with repeating patterns of α helices/ β sheets evident. The α 
helix of each finger interacts with the major groove of the DNA, and the repeating pattern 
of zinc finger elements ensures a strong DNA-protein interaction  [62]. The number of 
repeating ‘fingers’ can determine the specificity of this type of zinc finger-containing 
protein  [1]. Another example of a zinc finger DNA binding domain involves two α 
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helices held together by two cysteine-coordinated zinc atoms, similar in structure to the 
helix-turn-helix motif previously described. Like helix-turn-helix containing proteins, this 
type of zinc finger protein typically functions as a dimer, with one of the α helices 
interacting with the major groove. Notably, this type of zinc finger domain is found 
within the DNA binding domains of nuclear hormone receptors  [1,62]. Many other 
structural subclasses of zinc fingers exist  [64], but their properties are beyond the scope 
of this thesis. 
Leucine zippers constitute a third class of DNA binding domain. The leucine 
zipper motif is made up of an α helix, with adjacent regions for dimerization and DNA 
interaction  [62]. Dimerization is facilitated by hydrophobic, luecine-rich regions within 
each monomer, which come together to form a coiled-coil. Beyond the dimerization 
region, the helices of each monomer are separated, with the resulting structure resembles 
a Y-shape, and allowing for interaction with the major groove of DNA  [1,65]. 
Heterodimerization of DNA binding proteins, such as leucine zippers, can also occur, 
thereby expanding the number of possible DNA-binding specificities. 
Related to the leucine zipper is the helix-turn-helix motif, which consists of a 
short α helix connected by a loop to a second, longer, α helix. The loop is quite flexible, 
allowing the helix-loop-helix protein to fold on itself, thereby facilitating both 
dimerization and DNA interaction  [1,65]. Helix-loop-helix proteins can also form either 
homo- or hetero-dimers. 
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1.4.1 Nuclear Receptors 
Nuclear receptors (NRs) are a class of proteins that are responsible for sensing 
and responding to the presence of a variety of hydrophobic ligands, including steroids, 
retinoic acid, thyroid hormones, and vitamin A and D derivatives  [3]. Groups who used 
tritiated estradiol to isolate and characterize constituents that bind estrogen in the rat 
uterus  [66,67] first suggested the existence of protein receptors for steroid hormones in 
the 1960s. Advancing technology, specifically recombinant DNA technology in the 70s 
and 80s allowed for specific receptors to be cloned and sequenced. In 1985, the 
glucocorticoid receptor became the first nuclear hormone receptor cloned  [68], with 
estrogen receptor alpha (ERα) identified shortly thereafter  [69]. The NR superfamily 
now consists of 48 known members in humans, and has documented roles in processes 
such as metabolism, differentiation, and development [74].  
Collectively, the NR transcription factors share a common domain architecture, 
consisting of six regions  [3,70-72]. The most amino (N)-terminal domains contain the 
ligand (hormone)-independent activation function 1 (AF-1). This region allows for some 
transcriptional activity from the NR in the absence of ligand. Next, is the DNA-binding 
domain (DBD); a region characterized by a pair of zinc fingers, which bind to specific 
palindromic recognition elements within the DNA, termed hormone response elements 
(HREs). A hinge region provides flexibility and has been found to play a role in nuclear 
localization, DNA binding, and coactivator recruitment. The ligand-binding domain 
(LBD) contains the ligand-dependent activation function 2 (AF-2) and consists of 12 α-
helices arranged in three layers, forming an antiparallel “α-helix sandwich”. This region 
17 
 
contains interaction surfaces for coactivator and corepressor proteins. Lastly, the carboxy 
(C)-terminal domain, which is highly variable, facilitates receptor dimerization. 
The NR superfamily can be categorized into several subgroups, including steroid 
hormone receptors, retinoid X receptor (RXR) heterodimers, as well as two classes of 
orphan receptors [for which there are no known ligands], which function as either 
heterodimers with other NRs, or as monomeric receptors, binding HRE half-sites  
[70,73]. Steroid receptors typically reside in the cytoplasm, and translocate to the nucleus 
upon ligand binding; whereas, RXR heterodimers are usually retained in the nucleus 
regardless of ligand binding status  [74]. 
In the canonical mechanism of NR action, the ligand binds its cognate receptor in 
the cytoplasm or nucleus of the cell, depending on the receptor type, causing a change in 
receptor conformation that facilitates dimerization. Ligand-bound receptors then 
translocate to the nucleus if necessary and interact via the zinc fingers of the DBD with 
specific DNA sequences known as hormone response elements (HREs). HREs were 
originally thought to be found within the 5’ proximal regulatory region of genes, but are 
now known to also be found at distal enhancers  [71,75]. A pair of palindromic six 
nucleotide sequences separated by three nucleotides makes up the typical HRE, for 
example ERα recognizes the sequence AGGTCAnnnTGACCT  [76]. Once bound to the 
HRE, subsequent recruitment of coactivators leads to the decondensation of chromatin 
through active remodeling and histone modification. Receptor-coactivator complexes 
recruit general transcription factors and RNAPII, and maintain an open chromatin 
conformation to allow for transcription initiation and elongation. It is important to note 
that NR recruitment can also lead to transcriptional repression; both by actively 
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repressing expression in the absence of ligand through interaction with corepressor 
proteins  [71,77], and/or by antagonistically inhibiting the activity of other transcription 
factors  [71,78].  
The classical view of NR action, based primarily on biochemical studies at 
selected genes, does not provide a complete understanding of their functionality. 
Evolving technology, specifically chromatin immunoprecipitation coupled to genomic 
microarray (ChIP-chip) or high throughput sequencing (ChIP-Seq), has allowed for the 
evaluation of NR recruitment genome wide. The first NR to be mapped in this manner 
was ERα. Surprisingly, this analysis revealed a predominance of ERα binding occurring 
at regions far distal from the TSS of genes  [79]. Subsequent studies have confirmed that 
the majority of ERα binding occurs more than 10 kb from the nearest TSS  [80,81]; an 
observation that has been extended to other NRs, including glucocorticoid receptor (GR), 
peroxisome proliferator-activated receptor gamma (PPARγ), and vitamin D receptor 
(VDR)  [82-84]. The requirement for sequence specific binding motifs (HREs) has also 
been called into question as NRs have been found to interact with regions that do not 
contain HREs  [79,81], and analysis of NR cistromes has shown that NRs can bind at 
sites containing HRE half-sites as well as other noncanonical recognition sequences  [85].  
 
1.4.2 The Estrogen Receptor 
Estrogens are a family of steroid hormones, which are involved in regulating 
numerous processes ranging from development, to sexual maturation and behavior. On a 
cellular level, estrogens, most notably E2, are essential mediators of regulatory pathways 
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responsible for the normal proliferation and differentiation of cells  [86,87]. E2 has been 
epidemiologically and clinically linked to breast cancer incidence, and unsurprisingly, the 
deregulation of its downstream signaling cascades is a common feature of carcinogenesis  
[88]. 
The cellular effects of E2 are mediated through the estrogen receptor (ERα), 
which is primarily expressed in breast, uterus, ovary, testes, epididymis, bones, and brain  
[72]. In the classical mechanism of estrogen signalling, as in the canonical NR response 
previously described, ligand (E2) binding triggers receptor dimerization and interaction 
with estrogen response elements (EREs), specific palindromic DNA sequences within the 
regulatory regions of target genes  [76,89-91]. ER activation can also promote gene 
expression in the absence of direct DNA binding, through interactions with other DNA-
bound transcription factors such as activator protein-1 (AP-1) and specificity protein-1 
(Sp1)  [92-94]. Additionally, a Forkhead binding motif has been found to be enriched 
adjacent to a percentage of ER binding sites  [79], suggesting that the DNA-bound ER 
cooperates with Forkhead transcription factors on many targets.  
ERα activity is regulated at many levels  [72]; the most relevant of which for the 
purposes of this thesis is through its E2-dependent interaction with coregulator proteins. 
Importantly, E2 binding to the ER induces a conformational change that repositions the 
C-terminus and creates an adaptor surface that facilitates the recruitment of coregulator 
proteins. Coregulators [both coactivators and corepressors] that bind the ER can alter the 
chromatin architecture directly  [95], function as adaptors/bridging factors which recruit 
additional coregulator proteins to target genes  [96,97], or interact directly with 
components of the core transcriptional machinery  [98,99]. 
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1.5 Transcriptional Coregulators 
 Transcriptional coregulators are protein factors that can interact with transcription 
factors and modulate their activity. Many of these proteins contain a variety of enzymatic 
activities and can exert functional control over transcription  [100,101]. In addition, 
coregulators can act as bridging proteins, interacting with transcription factors and 
allowing for the assembly of large, multicomponent enzymatic complexes  [102]. 
Coregulators generally fall either into the categories of coactivators, which enhance gene 
expression, or corepressors, which are suppressive. Coactivators can be further classified 
as primary coactivators, which come into direct contact with the transcription factors, and 
secondary coactivators, which participate in the coregulator complexes but do not directly 
bind TFs  [102,103]. To date, almost 350 coregulators have been identified based on 
these criteria (www.NURSA.org). Collectively, these proteins play a critical role in 
cellular processes, and provide a level of diverse, dynamic, and adjustably-responsive 
control specifically for transcription.  
 
1.5.1 Steroid Receptor Coactivators 
As discussed in section 1.4.1, NRs are ligand-dependent transcription factors that 
regulate gene expression and affect various physiological functions. It was initially 
believed that NRs alone allowed RNAPII and general transcription factors to assemble at 
promoters and control transcription. However, when it was shown that overexpression of 
one NR could indirectly inhibit the activity of another, and that in vitro assays involving 
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only NRs and general transcriptional machinery produced at best modest transcriptional 
responses, it was suggested that NRs may share a common set of coregulatory effector 
proteins required for full transcriptional response.  [104-106] 
The first such coregulatory protein, steroid receptor coactivator 1 (SRC1/ 
NCOA1), was identified by Onate et al. in 1995  [107]. SRC1 was found to interact with 
NRs in a ligand-dependent manner, robustly activating transcription. Two other 
homologous proteins were cloned soon after, completing the p160 SRC family: SRC2 
(also known as NCOA2, TIF2, GRIP1)  [108,109], and SRC3 (also known as p/CIP, 
RAC3, AIB1, ACTR, TRAM1, NCOA3)  [110-114]. 
The steroid receptor coactivator (SRC) proteins are each approximately 160kDa 
in size, share 50-55% sequence similarity  [115], and have three conserved structural 
domains (Figure 1-4). The N-terminus contains a basic helix-loop-helix-Per/ARNT/Sim 
(bHLH-PAS) domain. This region is the most highly conserved among family members 
and is required for protein-protein interactions important for transcriptional activation, 
including direct interaction with transcription factors such as myogenin and myocyte-
specific enhancer factor 2C (MEF2C), and with enhancer proteins  [116,117]. Evidence 
also suggests that in the case of some family members, this domain can be implicated in 
nuclear localization  [118,119] and in proteasome-dependent turnover  [119]. The central 
nuclear receptor interaction domain (NRID) contains three LXXLL motifs that form 
amphipathic α-helices, and are responsible for direct contact with NRs. Sequences 
adjacent to this domain contribute to the specificity of NR binding  [120]. Finally, the C-
terminus contains two activation domains (AD1 and AD2), which allow for SRCs to 
interact with secondary coregulators. AD1 interacts with CBP (CREB-binding protein) 
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and the histone acetyltransferase (HAT) p300. AD2 interacts with the arginine 
methyltransferases coactivator-associated arginine methyltransferase 1 (CARM1) and 
protein arginine methyltransferase 1 (PRMT1). The C-terminal region of SRC1 and 
p/CIP contain minimal intrinsic HAT activity. However, specific substrates have not been 
well characterized, and this activity is of much lesser importance than the bridging role of 
SRCs in assembling complexes of transcriptionally active components.  
The series of events involved in NR- and coactivator-mediated transcriptional 
activation has been extensively characterized. In 2003, Métivier et al. used a 
comprehensive chromatin immunoprecipitation (ChIP)-based approach to provide 
evidence of the ordered, cyclical, and combinatorial recruitment of cofactors in response 
to E2 in MCF-7 cells  [97]. This study demonstrated that at least 30 different proteins 
become engaged on the pS2 promoter in the presence of E2, and elucidated the kinetics 
of cofactor recruitment over time; revealing three cycles of protein interaction. SRC1 or 
p/CIP was found to associate with pS2 in the two transcriptionally productive cycles post 
E2 treatment  [97]. Specifically, SRC1 and/or p/CIP were found to cycle on an off the 
promoter every 50 min after E2 treatment, initially found to interact 45 min after 
treatment  [97]. Recruitment of these SRC proteins corresponds with the presence of 
ERα, and in fact, involves their interaction with ERα  [97]. There are limitations with this 
study, including the fact that it focuses only on a single E2-responsive promoter, and that 
cycling rate in a population of cells is not necessarily reflective of physiological 
conditions. Nevertheless, it is clear that NR signaling in response to E2 is dynamic and 
includes a level of specificity and redundancy among coregulators, which ultimately 
work together to achieve the required transctiptional outcome. Once bound to the NR,   
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Figure 1-4 SRC structural domains and interacting proteins 
SRC proteins consist of three structural domains. The N-terminal basic helix-loop-helix-
Per/ARNT/Sim (bHLH-PAS) domain, the central nuclear receptor interaction domain 
(NRID), and the C-terminal domain, which consists of two activation domains (AD1 and 
AD2). SRCs coactivate nuclear receptors (NRs), as well as numerous transcription factors, 
and coordinate the recruitment of a variety of secondary coregulatory proteins. This is a 
representation of some of the SRC-interacting proteins, mapped to the region with which 
they make contact. Figure is reproduced from Johnson et al 2011 [121]. 
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SRC family members act as scaffolding proteins and recruit many secondary 
coregulators, including the acetyltransferase p300 and methyltransferase CARM1  
[122,123]. CBP/p300 and CARM1 can then both modify the histones, promoting 
transcriptional activation (Figure 1-5)  [124].  
SRC functional effects are ubiquitous, primarily due to the ability of the family 
members to interact with and modulate the activities of a wide range of transcription 
factors, in addition to NRs (Figure 1-4), such as NFκB  [125], SMADs  [126], E2F1  
[127], STATs  [128], RB  [129], and p53  [130]. Extending the number of cellular 
process that are impacted by SRCs, interactions have also been shown with a variety of 
oncogenes, tumor suppressors, kinases and phosphatases, ubiquitin and SUMO (small 
ubiquitin-related modifier) ligases, as well as with other coregulators.  
 
1.5.2 Post-translational Modifications of SRCs 
Numerous studies have demonstrated that SRCs undergo post-translational 
modifications (PTMs) in response to numerous stimuli. These PTMs include 
phosphorylation, ubiquitination, sumoylation, acetylation, and methylation. These 
modifications can affect protein stability, interaction with TFs and secondary 
coregulators, in addition to transcriptional activity of SRCs (Figure 1-6).  
Phosphorylation of SRCs can change their affinity for specific NRs and/or affect 
NR-dependent gene expression. SRC1 can be phosphorylated at Thr1179 and/or Ser1185 
in response to epidermal growth factor (EGF) or interleukin 6 (IL-6). This results in 
enhanced association with p300 and CBP and increases NR-dependent 
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Figure 1-5 SRC-mediated coactivation of NRs 
SRC proteins are recruited to liganded NRs, interacting through their LXXLL motifs in the 
central nuclear receptor interacting domain (NRID). Secondary coregulatory proteins and 
chromatin remodeling complexes such as SWI/SNF are then recruited through their- basic helix-
loop-helix-Per/ARNT/Sim (bHLH-PAS) or C-terminal AD1 and AD2 domains, respectively. As 
shown, p300/CBP interacts with SRCs via the AD1 domain, while CARM1 contacts AD2. These 
secondary coactivators modify the chromatin and bridge the NR complex with the general 
transcription machinery to elicit transcriptional activation. Figure reproduced from Johnson et al 
2011 [121]. 
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Figure 1-6 Functional consequences of SRC post-translational modifications 
In response to a variety of signals SRC proteins can be post-translationally modified, thereby 
affecting intracellular concentration, activity, and specificity. Documented modifications include 
phosphorylation, ubiquitination, sumoylation, acetyaltion, and methylation. Figure reproduced 
from Xu et al 2009 [141]. 
27 
 
transcription,   [131,132]. p/CIP (SRC3) contains nine sites (Thr24, Ser101, Ser 102, 
Ser505, Ser543, Ser857, Ser860, Ser867, Tyr1357) that can be phosphorylated by a 
variety of different kinases, including but not limited to MAPK, IKK, and AKT  [133-
136]. The ability to accept signals from multiple pathways, and the number of different 
kinases that can contribute to regulation p/CIP highlight the central nature of p/CIP, and 
other SRCs as integrators of many different signalling pathways. As an example of the 
functional consequences of p/CIP, phosphorylation of Tyr1357 increases its binding to 
p300 and transcription factors, thereby promoting ERα-, PR-, and NFκB-dependent 
transcription  [136]. In addition, p/CIP phosphorylation can lead to its redistribution to 
either the nucleus or to the cytoplasm, altering its availability to regulate different 
transcriptional effects  [118,137,138]. 
Two sites of ubiquitination have been identified within the NRID of p/CIP  [139]. 
Polyubiquitination at these sites occurs following phosphorylation events, linking 
transcriptional activation with p/CIP degradation and transcriptional turnover  
[139,140]. Sumoylation, in contrast, can protect SRCs against degradation, by targeting 
common lysine residues and preventing ubiquitination. Sumoylation can also cause 
SRCs to adopt a transcriptionally inert conformation  [141,142]. 
Acetylation and methylation of SRCs can also occur, affecting their affinity for 
interacting proteins. For example, p/CIP can be acetylated by p300 and CBP, which 
results in disassembly of the coactivator complex and terminates transcription  [123]. 
Methylation of p/CIP by CARM1 also causes complex dissociation  [143,144], and 
leads to p/CIP degradation  [144]. 
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Collectively, post-translational modification(s) of SRC proteins occur as the result 
of many different signalling pathways, and combine to fine-tune the coactivator 
potency, cellular concentration, and selectivity of the SRCs, ultimately allowing for 
precise regulation of gene expression programs  [145]. 
 
1.5.3 p/CIP  
p/CIP (p300/CBP interacting protein) was originally identified in a region of 
chromosome 20 (20q13) that is frequently amplified in breast cancer, and was 
consequently named amplified in breast cancer-1 (AIB1)  [110]. This member of the 
p160 family of steroid receptor coactivators was independently cloned by several other 
groups and assigned a different name by each: steroid receptor coactivator-3 (SRC3)  
[146], activator of thyroid hormone and retinoid receptor (ACTR)  [111], receptor 
associated co-activator-3 (RAC-3)  [112], thyroid hormone receptor activating molecule 
(TRAM)  [113], and p300/CBP interacting protein (p/CIP)  [114]. p/CIP is generally the 
name given to the mouse homolog of SRC3, however we use this name interchangeably 
when referring to either the mouse or human protein. These assigned names are quite 
revealing of function, as p/CIP has been shown to interact with and enhance the activity 
of several nuclear receptors, including ERα, retinoic acid receptor (RAR), PR, and 
thyroid hormone receptor (TR)  [95,112-114]. In addition, p/CIP interacts with a variety 
of coregulator proteins, including CBP and CARM1  [123,146]. 
  p/CIP expression is detectable in a multitude of tissue types, including muscle, 
heart, lung, placenta, pancreas, kidney, brain, liver, uterus, pituitary, testis, and mammary 
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gland  [111,113,126,146,147]. Mouse models in which p/CIP is knocked out exhibit 
growth retardation and a reduced adult body size, which appears to be in part due to 
reduced IGF-1 levels  [147,148]. While male reproductive function is slightly reduced, 
there are significant defects in female reproduction. In p/CIP null female mice, sexual 
maturation is delayed, mammary gland ductal growth is reduced, and reproductive 
potential is diminished  [147]. Estrogen levels were lower in p/CIP knockout mice when 
compared to age-matched wild type littermates, corresponding to the observed 
reproductive phenotype  [147].  
Additive severity of SRC knockouts was observed when double-knockout mouse 
models were generated, suggesting that there exist cooperative functions among family 
members. When SRC1 and p/CIP are simultaneously knocked out, most mice die before 
birth  [149]. Those who survive exhibit defects in metabolism; specifically, compromised 
regulation of genes involved in adipogenesis and mitochondrial uncoupling. Leptin levels 
are increased in these mice, and a defect in adaptive thermogenesis coupled with 
developmental arrest in intercapsular brown fat means they are resistant to obesity due to 
a high basal metabolic rate. 
 
1.5.4 p/CIP in Breast Cancer 
Each of the SRC family members has been found to be overexpressed in human 
cancers  [145], with roles in promoting cancer initiation, progression, and metastasis 
through a variety of pathways. p/CIP is the most frequently amplified SRC in cancer, 
with a notable association in hormone-promoted breast and prostate cancers  [145]. While 
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in normal breast tissue, p/CIP levels are typically low, in breast cancer, p/CIP mRNA is 
overexpressed in 13-64%  [110,150-152] of different tumor cohorts, and p/CIP protein is 
overproduced in 10-25%  [153-155]. Overexpression of p/CIP correlates with increased 
tumor size and grade, tamoxifen resistance, and poor disease-free survival  
[110,150,154,155].  
Several mouse models have been used to elucidate the exact role(s) of p/CIP in 
breast cancer initiation and progression. MMTV-driven overexpression of p/CIP in the 
mouse resulted in the formation of spontaneous mammary tumors, thereby solidifying the 
role of p/CIP as an oncogene  [156]. However, tumors were also observed in the uterus 
and pituitary in this model, the result of nonspecific MMTV-dependent expression. In 
addition, corresponding to observations from p/CIP knockout mouse models, p/CIP-
overexpressing mice have altered [hyperactive] IGF-1 signalling  [156]. In another 
model, p/CIP null mice harbouring the MMTV-v-ras transgene breast tumour incidence 
was decreased  [157]. This mouse model also displayed altered IGF-1 signaling; lack of 
p/CIP resulted in partial resistance to IGF-1, partly causing the suppression of mammary 
tumorigenesis. In the HER2/neu-induced mammary tumorigenesis model, p/CIP 
knockout also offered some protection from tumor development; with tumor formation 
delayed in HER2+/+;p/CIP +/- mice and completely suppressed in HER2+/+;p/CIP-/- mice  
[158]. Furthermore, compared with MMTV-HER2 control mice, MMTV-HER2 mice 
heterozygous for p/CIP showed decreased phosphorylation of HER2, cyclinD1, and 
cyclin E, and reduced activity of AKT, JUN N-terminal kinase and had a reduced rate of 
proliferation  [158]. Genetic ablation of p/CIP in MMTV-PyMT mice protected against 
lung metastasis, as compared to WT/PyMT mice [159]. The role of p/CIP in breast cancer 
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metastasis is attributed to its regulation of matrix metalloproteinases MMP2 and MMP9, 
and their ability to mediate epithelial-mesenchymal transition (EMT) and cellular 
invasiveness in this model system  [159].  
ER status can be used as an indicator to assess prognosis and determine treatment 
strategies in breast cancer  [160].  Since p/CIP acts as a coregulator for ERα, a great deal 
of research has focused on the ability of p/CIP to mediate ERα-dependent gene 
expression in the context of breast cancer. In the MCF-7 breast cancer cell line, p/CIP 
depletion results in reduced recruitment of ERα to its target gene promoters, 
corresponding with loss of transcription of these genes  [161]. Furthermore, the absence 
of p/CIP corresponds to decreased E2-mediated proliferation, survival, and soft-agar 
colony formation [123]. Despite these observations, the literature remains quite conflicted 
as to the significance of p/CIP in ER-dependent oncogenesis due to contradicting clinical 
data correlating p/CIP expression with ER status  [150,162]. 
In addition to its involvement in E2-responsive breast cencer, the role of p/CIP in 
hormone-independent breast cancer has also been characterized. ER-negative breast 
cancers are more aggressive and unresponsive to anti-estrogens  [163]. p/CIP promotes 
cellular growth of ER-negative cell lines, by coactivating E2F1-dependent transcription 
of genes including E2F1, cyclin E, and cyclin-dependent kinase 2 (CDK-2)  [127]. 
Growth and survival of breast cancer cells can also be modulated by p/CIP through its 
interaction with AP-1  [164], and its coactivating role in NFkB-dependent transcription 
has been linked with the expression of inflammation, immune response, and cell survival 
[165]. In addition there is evidence of a link between p/CIP overexpression and activation 
of the insulin-like growth factor (IGF)/PI3K/Akt signalling  [156,157]. This pathway is 
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related to cell growth, survival, and migration and is often found constitutively activated 
in cancer  [166]. 
There is extensive evidence linking p/CIP with breast cancer, and as discussed it 
participates in the regulation of a wide variety of pathways and processes important for 
oncogenesis. p/CIP expression is generally an indicator of poor prognosis, and can affect 
responsiveness to treatments(s)  [145,155].  Continued characterization of p/CIP-
regulated genes will provide greater insight into the molecular mechanisms it uses to 
promote cancer.  
 
1.6 Protein Arginine Methylation 
Arginine methylation is a post-translational modification found on both nuclear 
and cytoplasmic proteins, which has been implicated in many different cellular processes, 
including, but not limited to, transcriptional regulation, signal transduction, RNA 
processing, and DNA repair. Defects in arginine methylation are known to be involved in 
several disease processes, including cardiovascular disease, spinal muscular atrophy, and 
cancer  [167,168]. 
Early reports assert that approximately 2% of arginine residues in rat liver nuclei 
are methylated, suggesting that this is a commonly occurring post-translational 
modification  [169]. Arginine methylation involves the covalent addition of one or more 
methyl groups to the guanidino nitrogen of an arginine residue, adding bulkiness but not 
affecting charge. There exist three known forms of methylated arginine: monomethylated 
arginine (MMA), asymmetrically dimethylated arginine (ADMA), and symmetrically 
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dimethylated arginine (SDMA)  [170]. The generation of these modifications can be 
attributed to a family of proteins collectively known as Protein Arginine 
Methyltransferases (PRMTs). 
 
1.6.1 The Protein Arginine Methyltransferase Family 
To date, there have been 11 members of the protein arginine methyltransferase (PRMT) 
family identified  [171]. This protein family shares four conserved motifs that constitute 
the catalytic methyltransferase domain, with additional domains conferring substrate 
specificity (Figure 1-7). Members of the PRMT family can be subcategorized based on 
their structure, or more commonly, on their specific methyltransferase activity. Using S-
adenosyl-L-methionine as a donor molecule, Type I methyltransferases form ADMA, 
while Type II form SDMA, on the guanidino nitrogen(s) of arginine residues, both 
through a monomethylated intermediate (Figure 1-8)  [172]. A third type of PRMT (Type 
III) has more recently been suggested to only generate MMA. Type I is the most common 
class of methyltransferases, and includes PRMT1, PRMT2, PRMT3, PRMT4 (CARM1), 
PRMT6, and PRMT8. In comparison, only two family members are consistently 
categorized as Type II (PRMT5 and PRMT9). PRMT7 has been shown to act either as 
Type II or Type III, in a substrate-dependent manner. The final two members of the 
family (PRMT10 and PRMT11) have yet to be enzymatically classified  [171]. 
Most PRMTs methylate glycine- and arginine-rich patches (GAR motifs) within 
their substrates  [173], although specific recognition sites for each of the family members 
are not well characterized. PRMT4, more commonly known as CARM1, is unusual   
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Figure 1-7 The Protein Arginine Methyltransferase Family 
Schematic representation of the 11 members of the protein arginine methyltransferase (PRMT) 
family. Each member of the family contain at least one conserved methyltransferase domain with 
signature motifs I, post-I, II, and III and a THW loop. Unique domains are thought to contribute 
to substrate specificity, and are shown in yellow. CARM1 is identified herein as PRMT4. Figure 
reproduced from Esse 2012 [167]. 
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Figure 1-8 Types of methylation on arginine residues 
Type I, II, and III PRMTs generate monomethylated arginine (MMA) on one of the guanidino 
nitrogen atoms. Subsequent generation of asymmetrically dimethylated arginine (ADMA) is 
catalyzed by Type I PRMTs (PRMT1, PRMT2, PRMT3, PRMT4/CARM1, PRMT6, PRMT8), 
while Type II PRMTs (PRMT5, PRMT9) produce symmetrically dimethylated arginine residues 
(SDMA). PRMT7 can act as either a Type II or III PRMT, and PRMTs 10 and 11 have not yet 
been enzymatically classified. Figure reproduced from Yang et al 2013 [166]. 
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among PRMTs since its substrates do not contain this GAR motif. CARM1 has been 
found instead to methylate proline-, glycine-, methionine-rich (PGM) regions  [174].  
 PRMTs are ubiquitously expressed, and affect a variety of important cellular 
processes, including RNA processing, DNA repair, signal transduction, and 
transcriptional regulation  [170,171]. Of particular interest for the purposes of this thesis 
is the role of PRMTs in transcription. Protein arginine methylation was initially detected 
on histones  [169], and occurs on the N-terminal tails of histone H3, H4, and H2A  
[2,171,175]. Notably, there are several arginine residues within histone H3 that become 
methylated (H3R2, H3R8, H3R17 and H3R26)  [42,171]. Asymmetric dimethylation of 
histone H3 generally correlates with activation of transcription  [171,176].  
Methylation of arginine residues also affects a wide array of non-histone 
transcriptional regulatory proteins, including transcription factors, coregulators, 
elongation factors, and RNAPII. Participation of PRMTs as components of coregulatory 
complexes are well known to modulate the activity of NRs  [98,177], as well as other TFs  
[178]. In addition, arginine methylation of coregulatory proteins such as p/CIP and CBP 
can affect their ability to form complexes, and their stability  [143,144]. The PRMT 
family members PRMT1 and PRMT5 have been shown to methylate the transcriptional 
elongation factor SPT5 in its RNAPII-binding domain, resulting in transcriptional 
pausing, wherein the engaged RNAPII accumulates just downstream of the promoter 
region [179]. Furthermore, several components of the transcriptional elongation-
associated Paf1c complex has been shown to interact with H3R17me2, thereby linking an 
additional PRMT, CARM1, with elongation  [180]. Finally, the C-terminal domain of 
RNAPII can be methylated by CARM1, and contributes to transcriptional activation, in 
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part by creating a docking site for the arginine methylation effector proteins such as 
TDRD3  [181]. 
 
1.6.2 CARM1 
Coactivator Arginine Methyltransferase 1 (CARM1), also known as PRMT4, is a 
Type I PRMT originally identified based on its ability to interact with GRIP-1 (SRC-2), a 
member of the p160 family of nuclear receptor coactivators  [123]. CARM1 has since 
been shown to interact with the two other members of the p160 family, SRC1 and SRC3 
(more commonly referred to in this thesis as p/CIP). CARM1 was the first of the PRMTs 
to be shown to regulate transcription  [123]. Its role as a secondary coregulator of 
transcription, synergistically enhancing gene expression of steroid-hormone-regulated 
genes has been extensively studied  [117].  
CARM1 methylates substrates that can be broadly classified as possessing RNA-
binding properties (PABP1, HuR, HuD, and splicing factors)  [182-184], and substrates 
that are involved in transcriptional regulation, including several residues of histone H3 
(H3R17, H3R26)  [185], p/CIP  [143,144], and CBP/p300  [186,187]. Notably, the 
methyltransferase activity of CARM1 is essential for its transcriptional effects  [177].  
CARM1 deletion in the mouse model revealed embryos that were small in size, 
and die late in development or shortly after birth  [188]. An elevated rate of lethality was 
also noted for heterozygotes between birth and weaning. CARM1 knockout mice were 
found to have insufficient lung development, blocked T-cell development in the thymus, 
and altered lipid metabolism. CARM1 null mouse embryonic fibroblasts (MEFs), isolated 
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from E12.5 embryos, do not support the methylation of CARM1 substrates, including 
histone H3, p300 and PABP1. Furthermore, CARM1-/- MEFs were found to be defective 
in E2-dependent signalling and in NFkB signalling pathways  [188]. 
 
1.6.3 CARM1 in Cancer 
CARM1 is overexpressed in breast, prostate, and colorectal cancer  [189-191]. 
Recently, several large-scale clinical studies have confirmed that CARM1 levels are 
elevated in aggressive breast tumors  [192,193]. Furthermore, the expression of CARM1 
in breast cancer is a predictor of diminished survival, and of poor disease-free survival  
[192,193]. Notably, CARM1 expression plays a significant role in ERα-induced 
proliferation and differentiation of the MCF-7 breast cancer cell line  [194]. In fact, ERα-
regulated gene expression has been shown to rely on the presence of both p/CIP and 
CARM1  [195]. Since, p/CIP itself has minimal intrinsic enzymatic activity, and 
primarily acts to recruit additional coregulators, it follows that CARM1 is likely an 
important mediator of the oncogenic effects attributed to these ERα-dependent genes.  
 CARM1-dependent methylation has been implicated in many additional pathways 
and processes commonly deregulated in cancer  [170], including the DNA damage 
response  [196], regulation of the cell cycle  [195], and WNT signalling  [197]. In 
addition, CARM1 is involved in promoting a favorable microenvironment for tumor 
growth and metastasis  [198,199]. Collectively, accumulating evidence alludes to the 
importance of CARM1 and regulation of protein arginine methylation in oncogenesis. 
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1.7 Thesis Overview 
The work presented within this thesis aims at extending our current understanding 
of the role that the arginine methyltransferase CARM1 plays in global transcriptional 
regulation. To this end we took a top-down approach in two quite different model 
systems, using large-scale ChIP-on-chip and ChIP-Seq approaches in conjunction with 
expression microarray analysis to initially identify global effects. We subsequently 
refined our observations to specific critical pathways and/or target genes regulated by 
CARM1. 
Chapter 2 details our assessment of CARM1 as part of a coregulatory complex 
with the steroid receptor coactivator p/CIP in an estrogen-dependent transcriptional 
context. In this study, we show, using a ChIP-on-chip approach, that in response to 
stimulation with E2, a p/CIP/CARM1 complex is recruited to a subset of responsive 
promoters in MCF-7 breast cancer cells. Following extensive bioinformatic 
characterization, we ultimately focused on Jak2, a member of the JAK/STAT signalling 
pathway, and one of the direct E2-dependent targets of p/CIP/CARM1. E2-dependent 
histone modifications at the Jak2 promoter reflected recruitment of a functional 
p/CIP/CARM1 complex, and were generally transcriptionally permissive. Modest 
increases in Jak2 expression were observed, leading us to theorize that an additional 
factor(s) may be required for a more substantial transcriptional response. Notably, 
however, E2-induced expression of Jak2 was diminished when p/CIP or CARM1 were 
depleted, suggesting that the p/CIP/CARM1 complex is required for the observed 
transcriptional response. Collectively, the results of this study led us to suggest that E2-
dependent recruitment of the p/CIP/CARM1 complex causes JAK2 to become ‘poised’ 
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for transcription, a finding that may be extendable to other target genes and signalling 
pathways. 
The work we present in Chapter 3 takes a novel approach to characterizing 
CARM1-dependent transcriptional regulation. Previous assessment of the role of 
CARM1 in gene expression has been primarily focused on its ability to interact with, 
methylate, and modulate the function of the transcription factors and transcriptional 
regulators with which it interacts. No consideration had been given to the independent 
recruitment of CARM1 on a genome-wide scale, and little to the ability of CARM1 to 
affect expression by directly modifying the chromatin. For this study, we utilized a 
mouse embryonic fibroblast (MEF) model system in which CARM1-dependent gene 
regulation could be assessed without limiting its functionality to specialized cellular 
programs or particular disease states. Again beginning with a genome-wide approach 
[this time using ChIP-Seq], we identified genomic regions to which CARM1 is recruited. 
Subsequent characterization of binding events suggests a role for CARM1 in 
transcriptional elongation, and implicates the transcription factor PAX1 as a potential 
mediator of CARM1 genomic recruitment. When we identified genes that are 
differentially expressed when CARM1 is absent, we found that direct recruitment of 
CARM1 was not essential for its transcriptional effects. Functional analysis focused us 
on a critical role for CARM1 in cellular growth and proliferation, and we showed that in 
the absence of CARM1, the expression of many cell cycle regulators is dramatically 
altered. When subjected to further replicative stress, cell cycle-compromised, CARM1-
null cells did not survive.  
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 Collectively, the work presented herein highlights a few of the mechanisms 
through which CARM1 can affect global transcriptional regulation.  
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  Chapter 2
 β-Estradiol-dependent activation of the JAK/STAT 2
pathway requires p/CIP and CARM 
2.1 Introduction 
Transcriptional activation is a highly dynamic process that involves a large and 
diverse class of proteins known as coactivators. Coactivators mediate specific 
transcriptional responses by utilizing several interrelated mechanisms involving 
chromatin remodeling and covalent modification of histones. These mechanisms often 
work cooperatively to alter the structural restrictions imposed by packaging of DNA into 
chromatin. Additionally, many coactivators function as adaptors/bridging factors to 
recruit additional coactivator proteins to target genes [1]. Detailed genome-wide 
chromatin immunoprecipitation (ChIP) studies of binding sites for various transcription 
factors, such as the estrogen receptor (ER), have provided significant insight into the 
dynamics of coregulator activity at selected targets [2]. For example, the ER undergoes a 
cyclic pattern of association and dissociation at selected ER targets [2,12], and its 
association with DNA often coincides with the recruitment of several ERα-interacting 
complexes. These complexes consist of various combinations of coregulators, the basal 
transcriptional machinery, as well as RNA polymerase II [3]. The p/300 CBP interacting 
protein (p/CIP), also known as SRC3/AIB1/ACTR/RAC3, [4–9] belongs to a family of 
steroid receptor coactivator (SRC) proteins containing two additional family members 
(SRC1 and SRC2). p/CIP interacts directly with the liganded ER, and functions primarily 
as a bridging factor that binds to hormone-bound nuclear receptors to promote coactivator 
complex assembly [10,11]. ChIP assays have established that p/CIP associates with many 
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endogenous ER target genes in response to 17β-estradiol (E2), including pS2 [3], 
cathepsin D [12] and cyclin D1 [13]. Additionally, p/CIP interacts with other liganded 
nuclear receptors [5,7–9] and other classes of transcription factors such as E2F [14] and 
NFkB [15]. 
Several studies have shown that p/CIP undergoes a variety of posttranslational 
modifications in response to extracellular signals such as phosphorylation, acetylation, 
methylation, ubiquitination, and sumoylation [10,16–20]. These modifications provide an 
important regulatory mechanism that defines the combinatorial associations with 
additional coactivators, resulting in the formation of diverse multimeric complexes, 
which generate distinct gene expression programs. The coactivator-associated arginine 
methyltransferase protein (CARM1) is one such coactivating partner that interacts with 
the carboxy terminus of p/CIP as well as other SRC proteins. CARM1 has been shown to 
methylate proteins involved in RNA processing as well as specific arginines at positions 
17 and 26 on histone H3, suggesting that CARM1 plays a direct role in gene transcription 
[21,22]. Furthermore, several studies have demonstrated a correlation between 
recruitment of CARM1, methylation of histone H3, and activation of several steroid 
responsive genes [23–26]. Sequential ChIP analysis has identified a complex consisting 
of p/CIP and CARM1 on several estrogen responsive genes [16,27,28], and CARM1 
synergizes with p/CIP to activate NR-dependent transcription [29–31]. Collectively, these 
studies suggest that direct recruitment of CARM1 by p/CIP represents an essential 
activating step for ER-dependent transcription. In the present study, we have used 
sequential ChIP–reChIP assays in conjunction with genome-wide microarray screening to 
identify E2-dependent gene promoter targets of the p/CIP/CARM1 complex. Importantly, 
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our studies identify the JAK2 promoter as a novel target for the p/CIP/CARM1 complex 
in response to E2, indicating a novel interplay between ER signaling and the JAK/STAT 
pathway at the level of transcription, which may have implications in ER positive breast 
cancers where the JAK/STAT signaling pathway is constitutively active. 
2.2 Results 
2.2.1 Identification of genes directly targeted by the p/CIP/CARM1 
complex in response to β-estradiol (E2) 
To identify p/CIP/CARM1 target genes which play a role in E2-dependent 
signaling we embarked on a genome-wide chromatin immunoprecipitation assay 
approach based on DNA Selection and Ligation (ChIP-DSL) [32]. Briefly, MCF-7 cells 
were treated with E2 for 45 min and a standard ChIP assay was performed using an 
antibody against p/CIP. The immunoprecipitated material was then reChIPed using a 
CARM1-specific antibody. The resulting p/CIP/CARM1-enriched and input DNA was 
then purified, biotinylated, and combined with 40,000 unique predesigned 
oligonucleotides. After annealing, the biotinylated DNA was selected using streptavidin 
Sepharose and hybridized to a 20,000 gene promoter array (Figure 2-1A). The 
identification of E2-dependent p/CIP/CARM1 targets was based on the following criteria: 
first, we established a list of genes displaying a statistically significant enrichment 
relative to input (p<0.05) regardless of the treatment. From this list, genes that displayed 
a 2-fold or greater enrichment in the E2-treated cells relative to control were identified 
(i.e. a twofold or greater enrichment was observed in cells treated with E2 as compared to 
the untreated cells). The experiment was performed in triplicate and based on these   
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Figure 2-1 ChIP-DSL analysis of p/CIP/CARM1 target genes in MCF-7 cells. 
(A) Sequential ChIP-reChIP coupled to DNA Selection and Ligation (ChIP-DSL) was 
used to assess global promoter occupancy by the p/CIP/CARM1 complex. Sequential 
ChIP-reChIP was performed using either IgG or anti-p/CIP followed by anti-CARM1 
antibodies in control and 17β-estradiol stimulated MCF-7 cells. Total input and antibody-
enriched DNA were biotinylated and annealed to a 40mer oligonucleotide pool.  
Annealed oligonucleotides were selected for with streptavidin-coated metal beads, and 
appropriate 40mers are ligated to form an 80mer which is then labelled and hybridized to 
the Hu20K array, which contains sequences from 20,000 unique human promoters. 
Scatter plots of (B) control and (C) 17β-estradiol stimulated p/CIP/CARM1 ChIP (y axis) 
versus input (x axis) from three independent biological replicates, demonstrating a normal 
cluster distribution. (D) Venn diagram depicting the overlap in genes enriched from three 
independent ChIP-DSL experiments (Rep 1 to 3). 
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criteria we identified 204 gene promoters that become co-occupied by p/CIP and CARM1 
in response to E2 treatment for 45 min (Figure 2-1B-C & Table B-1). To validate the 
ChIP-DSL analysis, we performed independent ChIP–reChIP experiments for a random 
set of target genes identified (Figure 2-2). In the majority of cases tested, treatment with 
E2 resulted in the simultaneous recruitment of p/CIP and CARM1, indicating that the 
false positive rate was extremely low. It should be emphasized that in our experimental 
protocol we have identified gene targets for p/CIP/CARM1 as a consequence of E2 
treatment; which may include genes directly regulated by the ER, as well as genes 
indirectly regulated by the ER through its association with other transcription factors, or 
via a nongenomic pathway. 
 
2.2.2 The ER interacts with a fraction of p/CIP/CARM1 target gene 
promoters 
To better validate our analysis, we compared our results with two previous studies 
examining direct E2-dependent ER binding on a genome-wide scale [33,34]. Carroll et al. 
discerned 3665 unique E2- dependent ER binding sites using a ChIP–chip Affymetrix 
Human tiling array approach [33], while Welboren et al. used a ChIP-Seq approach to 
identify 10,205 genome-wide ER-interaction sites [34]. Using the published 
chromosomal locations for ER-binding targets identified in these studies, we 
distinguished known genes present within and/or adjacent to these genomic sites. Next, 
we conducted direct gene-by-gene comparisons of p/CIP/CARM1 targets in our study 
with the ER targets identified in each of the previous studies. An important consideration   
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Figure 2-2 ChIP analysis of selected direct p/CIP/CARM1 target genes 
Control and 17β-estradiol stimulated MCF-7 cells were cross-linked with 1% formaldehyde, and 
sequential ChIP-reChIP was performed using either IgG or anti-p/CIP followed by anti-CARM1 
antibodies. Recovered DNA was assayed by PCR using primers corresponding to the promoter 
regions indicated. Selected target genes shown are pS2, CCNA2, NFKB1, DYRK1A, WBP11, 
IL15RA, TGFB1, NEK4, KRAS2, and MAPK4 
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for the purposes of this comparison is that while our analysis was restricted to the 1 kb 
proximal promoter regions of genes, the studies conducted by both the comparison 
groups encompassed binding sites throughout the entire genome. Notably, in each of 
studies used for comparative analysis, only a small proportion (4–7%) of ER interaction 
sites were located within promoter regions. Nevertheless, our analysis indicated that 
65/204 (32%) [33] and 118/204 (58%) [34] (Figure 2-3A) of identified p/CIP/CARM1 
complex targets have previously been shown to display ER binding following E2 
treatment. Moreover, 59/204 (29%) p/CIP/CARM1 complex targets were ER binding 
targets common to both studies, and were therefore considered to be high confidence ER 
interactors (Figure 2-3B, Table 2-1). 
 
2.2.3 Binding site enrichment in the promoters of p/CIP/CARM 
target gene promoters 
Since our p/CIP/CARM1 target genes may include genes directly and/or 
indirectly regulated by the ER, we examined 1 kb upstream promoter sequences of the 
gene targets for transcription factor binding site enrichment, to discern potential 
mechanisms for E2-dependent p/CIP/CARM1 binding. Using a candidate scanning 
approach, we conducted a search for enriched motifs within our target gene promoter 
sequences. Previous studies have shown that in addition to directly binding ER-binding 
elements (EREs) in response to ligand, the ER associates with C/EBP [35], and can also 
be targeted to the DNA via interaction with Oct [36,37], Sp1 [38,39] and/or AP-1 
[40,41]. Forkhead motifs were also of interest, as evidence has linked the presence of the   
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Table 2-1 p/CIP/CARM1 target genes bind the ER. 
Gene ID Accession Number Description 
TLR3 NM_003265 Transmembrane receptor 
DBC1 NM_014618 Peptidase 
LAP3 NM_015907 Peptidase 
LDN12 NM_012129 Calcium-independent cell-cell adhesion 
SLC4A5 NM_021196 Solute carrier family 4, sodium bicarbonate cotransporter, member 5 
PTER NM_030664 Phosphotriesterase related 
TRAF3 NM_003300 TNF receptor-associated factor 3/apoptosis 
LETM1 NM_012318 Leucine zipper-EF-hand containing transmembrane protein 1 
GSF4/CADM1 NM_014333 Cell adhesion molecule 1/tumour suppressor 
OCA2 NM_000275 Oculocutaneous albinism II 
SLC26A1 NM_022042 Solute carrier family 26 (sulfate transporter), member 1 
FRMD1 NM_024919 FERM domain containing 1 
4BP1 NM_153029 NEDD4 binding protein 1 
CTNND1 NM_001331 Catenin (cadherin-associated protein), delta 1 
CDH7 NM_033646 Cadherin 7, type 2 
RAD9B NM_152442 RAD9 homolog B (S. cerevisiae)/DNA replication 
ECT2 NM_018098 Epithelial cell transforming sequence 2 oncogene 
PCSK5 NM_006200 Proprotein convertase subtilisin/kexin type 5 
GATM NM_001482 Glycine amidinotransferase (L-arginine:glycine amidinotransferase) 
TUBGCP6 NM_020461 Tubulin, gamma complex associated protein 6 
KCTD16 XM_098368 Potassium channel tetramerisation domain containing 16 
TGFB1 NM_000660 Growth factor 
NEK4 NM_003157 Enzyme 
RPS4X NM_001007 Ribosomal protein S4, X-linked 
STARD4 NM_139164 StAR-related lipid transfer (START) domain containing 4 
HRASLS NM_020386 HRAS-like suppressor 
PKP4 NM_003628 Plakophilin 4/cell adhesion 
SMARCAL1 NM_014140 SWI/SNF related, matrix associated,  regulator of chromatin,  a-like 1 
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CD9 NM_001769 CD9 molecule/cell adhesion 
C9orf95 NM_017881 Orf 
TMEM16F XM_113743 Transmembrane protein 16F 
IVNS1ABP NM_006469 Influenza virus NS1A binding protein 
DDX54 NM_024072 DEAD (Asp-Glu-Ala-Asp) box polypeptide 54/tranascriptional regulator 
ITPKB NM_002221 Inositol 1,4,5-trisphosphate 3-kinase B 
POLR2F NM_021974 Polymerase (RNA) II (DNA directed) polypeptide F 
LAMA1 NM_005559 Laminin, alpha 1/cell adhesion protein 
TSHB NM_000549 Thyroid stimulating hormone, beta 
RDH10 NM_172037 Retinol dehydrogenase 10 (all-trans) 
KCNQ1 NM_000218 Potassium voltage-gated channel, KQT-like subfamily, member 1 
KCTD3 NM_016121 Potassium channel tetramerisation domain containing 3 
PCP4 NM_006198 Purkinje cell protein 4 
LRFN4 NM_024036 Leucine rich repeat and fibronectin type III domain containing 4 
ABAT NM_000663 4-aminobutyrate aminotransferase 
PTPRJ NM_002843 Protein tyrosine phosphatase, receptor type, J 
JAK2 NM_004972 Janus kinase 2 (a protein tyrosine kinase) 
GPR132 NM_013345 G protein-coupled receptor 132 
HARS NM_002109 Histidyl-tRNA synthetase 
MDS009 NM_020234 DTWD1 DTW domain containing 1 
POLG NM_002693 Polymerase (DNA directed), gamma 
HSD17B12 NM_016142 Hydroxysteroid (17-beta) dehydrogenase 12 
AKAP13 NM_006738 A kinase (PRKA) anchor protein 13 
DPYS NM_001385 Dihydropyrimidinase 
DYRK1A NM_101395 Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A 
EDC3 NM_025083 Homo sapiens enhancer of mRNA decapping 3 homolog (S. cerevisiae) 
SLC39A10 XM_047707 Solute carrier family 39 (zinc transporter), member 10 
SAMD3 NM_152552 Sterile alpha motif domain containing 3 
FLRT2 NM_013231 Fibronectin leucine rich transmembrane protein 2/cell adhesion 
MGC14156 NM_032906 PIGY phosphatidylinositol glycan anchor biosynthesis, class Y 
MXD3 NM_031300 MAX dimerization protein 3 
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Figure 2-3 Binding site enrichment analysis of p/CIP/CARM1 target promoter 
sequences 
(A) Pie charts indicating the proportion of p/CIP/CARM1 target genes that are known to bind 
the ER based on comparison with ChIP-chip analysis performed by Carroll et al. (top) and 
ChIP-Seq analysis performed by Welboren et al. (bottom). (B) Venn diagram showing overlap 
of p/CIP/CARM1 direct target genes (highlighted in blue) with ER-binding sites identified by 
ChIP-chip reported by Caroll et al. and identified by ChIP-Seq reported by Welboren et al. 59 
p/CIP/CARM1 target genes were common to both the Carroll et al. and Welboren et al. 
analysis, and were considered to be high confidence ER-binding targets. (C) Bar graph showing 
the number of individual p/CIP/CARM1 target promoters that contain ERE, Sp1, AP-1, FoxA1, 
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FoxA1/ HNF3α motif to ER recruitment [33,42]. When p/CIP/CARM1 target gene 
promoter sequences were compared to a background control set of human housekeeping 
gene promoters, many enriched putative binding motifs were identified (Table B-2). 
While EREs were shown as being significantly enriched among p/CIP/CARM1 complex 
promoters, it was not the most prevalent motif when ranked either by p-value or by 
enrichment score. Sp1, C/EBP, Oct, FoxA1, and AP-1 motifs were all found to be more 
significantly enriched than EREs among the p/CIP/ CARM1 target gene promoters we 
identified. Evaluation of these consensus sites within the individual promoter sequences 
confirmed the presence and relative abundance of the motifs, with approximately 12% of 
target promoters containing one or more EREs, 31% C/EBPα motifs, 24% Sp1, 20% Oct, 
10% FoxA1, and 9% contain putative AP-1 sites (Figure 2-3C). Several of the promoters 
contain consensus sites for more than one of the considered transcription factors. 
EREs occurred simultaneously more often with C/EBP, Oct, and Sp1 motifs 
rather than with FoxA1 or AP-1 motifs (Figure A-1). While a negative correlation 
between ERE and AP-1 elements has previously been observed [33], our findings are 
contrary to previous reports [33,42] in that FoxA1 motifs did not consistently coincide 
with the presence of EREs. This discordance is likely due to our exclusive focus on the 
proximal promoter, since Kwon et al. also noted limited association of FoxA1 sites with 
proximal promoter ER binding events as identified by ChIP-DSL [43]. The overall 
enrichment pattern of putative transcription factor motifs did not change for the 59 
p/CIP/CARM1 target genes that are considered to be high confidence ER binding targets 
(Figure B-2a) or for targets transcriptionally upregulated following E2 treatment (Figure 
B-2b). 
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Collectively, this analysis demonstrates a consistent pattern of enriched motifs 
among p/CIP/CARM1 complex target promoters, and suggests that transcription factor 
crosstalk is likely the favored mechanism of E2-dependent p/CIP/CARM1 recruitment at 
the proximal promoters of target genes, regardless of ER binding status or transcriptional 
state. The presence of EREs suggests that the classical response with direct binding of the 
ER is also involved, albeit to a lesser extent. 
 
2.2.4 A proportion of p/CIP/CARM1 target genes are directly 
regulated by E2 
To correlate p/CIP/CARM1 binding data with the E2-dependent transcriptional 
response, we performed gene expression profiling using MCF-7 cells treated with 10 nM 
E2 for 12 h. RNA was isolated, reverse transcribed and hybridized to Affymetrix 
microarrays. A list of differentially expressed genes from three independent experiments 
was generated (p-value<0.05 was used as the cutoff). Based on these criteria, we 
identified 396 and 231 genes that were significantly upregulated or downregulated, 
respectively, following E2-treatment (Figure 2-4A), consistent with previous expression 
profiling studies [43,44]. Comparison of the microarray expression data with the ChIP-
DSL results determined that 33 (16.2%) targets proximally bound by the p/CIP/CARM1 
complex are significantly upregulated, and 8 (3.9%) p/CIP/CARM1 target genes were 
downregulated following E2 treatment (Table 2-2). The reliability of this analysis was 
confirmed by quantitative real-time PCR (qPCR) analysis of selected genes (Figure 2-
4B). These findings suggests that proximal binding may be more relevant for 
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transcriptionally upregulated genes, and shows that while the p/CIP/CARM1 complex 
may have a preferential role in transcriptional activation, it also plays a direct role in the 
repression of specific genes. 
 
2.2.5 The JAK/STAT signaling pathway is a central target for 
p/CIP/CARM1 
Using Ingenuity Pathway Analysis we were able to identify a number of networks 
consisting of target genes that are functionally or biochemically linked. Several of the 
genes play a role in disease (Figure 2-5A), and the molecular and cellular functions most 
associated with p/CIP/CARM1 target genes have been linked to the initiation and 
progression of cancer (Figure 2-5B). We found that the network containing one of the 
highest number of functionally linked targets is the canonical JAK/STAT signaling 
pathway. Several interconnected genes within this pathway are direct targets for p/CIP 
and CARM1, including janus tyrosine kinase 2 (Jak2), the interleukin 15 receptor 
(Il15ra), and Pias2-a sumo ligase, which functions as a coregulator for STAT proteins 
(Figure 2-4C, colored targets). Adding to the implied relevance of p/CIP/CARM1-
mediated regulation of this pathway, Stat3 and Stat5 (Figure 2-4C, gray targets) were also 
identified as E2-dependent p/CIP/CARM1 binding targets, however, they were not 
included on the final list as they did not meet the applied statistical criteria. We focused 
our initial analysis on the Jak2 gene. JAK2 plays a central role in JAK/ STAT signaling 
and mammary gland development, and hyperactivation of this protein is associated with 
71 
 
cancer initiation. Importantly, functional ablation of JAK2 in mice protects against the 
onset of mammary tumorigenesis [45]. 
 
2.2.6 E2-dependent regulation of JAK2 
JAK2 expression was assessed using qPCR following E2 treatment of MCF-7 cells 
for various time periods. We observed an initial decrease in Jak2 expression 1 h 
following E2 treatment, and a gradual increase in expression thereafter, such that at 12 
and 24 h the expression levels are consistent with preliminary expression array data, with 
an approximately 1.5-fold increase in expression when compared to the untreated control 
(p<0.05) (Figure 2-4B). Analysis of JAK2 protein levels exhibit a corresponding trend, 
with a modest increase (~1.3 fold) in protein expression after 12 and 24 h of E2 
stimulation, followed by a decrease to control unstimulated expression levels at 72 h 
(Figure 2-4D). 
To validate recruitment of p/CIP and CARM1 to specific regions of the Jak2 
promoter we performed ChIP assays. For the purposes of this analysis, we used a region 
of the promoter that corresponds to a region 787 to 950 bp upstream of the transcriptional 
start site (TSS) (Figure 2-6A). An ERE-Sp1 half-site was identified within this portion of 
the Jak2 promoter. 
Cells were treated with E2 for 45 min and promoter occupancy was assessed by 
sequential ChIP assay using specific antibodies recognizing p/CIP and CARM1. In 
addition, ChIP assays were performed using an antibody against the ER to assess a   
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Figure 2-4 p/CIP/CARM1 target genes are directly regulated by E2.  
(A) Differentially expressed genes after E2-stimulation relative to unstimulated control  cells. (B) 
Realtime RT-PCR analysis of pS2, JAK2, and MAPK4 following stimulation of MCF-7 cells 
with 17β-estradiol for 1hr, 3hr, 12hr, and 24hrs. Data is expressed as means and standard error of 
the mean from repeated experiments, performed independently (pS2 n=7, JAK2 n=7, MAPK4 
n=3). Paired student’s t-test was performed and statistically significant changes from untreated 
samples are indicated. (C) Canonical pathway diagram, highlighting statistically significant 
p/CIP/CARM1 complex direct targets in color. Targets in grey are bound by p/CIP/CARM1 but 
do not meet statistical criteria. (D) Western blot showing JAK2 levels in MCF7 cells following 
17β-estradiol stimulation of MCF7 cells for 1, 3, 12, 24, 48, and 72 hrs. Relative abundance of 
protein levels at 12, 24, 48, and 72hr time points was quantified by densitometry.  
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Table 2-2 Genes directly regulated by the p/CIP/CARM1 complex a 
Gene ID Accession Number Description 
Genes Activated by 
E2   
NFKB1 NM_003998 Nuclear factor of kappa light polypeptide gene enhancer 
MOCOS NM_017947 Enzyme 
JAK2 NM_004972 Janus kinase 2 (a protein tyrosine kinase) 
STARD4 NM_139164 StAR-related lipid transfer (START) domain containing 4 
HARS NM_002109 Histidyl-tRNA synthetase 
IGSF4/CADM1 NM_014333 Cell adhesion molecule 1/tumour suppressor 
KCTD3 NM_016121 Potassium channel tetramerisation domain containing 3 
GTF2E2 NM_002095 General transcription factor IIE, polypeptide 2, beta 34kDa 
ZIM3 NM_052882 Zinc finger, imprinted 3/transcription factor 
PDCD8 NM_004208 Enzyme/cell death 
WBP11 NM_016312 WW domain binding protein 11 
PRKRIR NM_004705 Protein-kinase, interferon-inducible  RNA dependent inhibitor 
ZNF567 NM_152603 Transcription factor 
IVNS1ABP NM_006469 Influenza virus NS1A binding protein 
BMI1 NM_005180 BMI1 polycomb ring finger oncogene 
M6PR NM_002355 Mannose-6-phosphate receptor (cation dependent) 
HSD17B12 NM_016142 Hydroxysteroid (17-beta) dehydrogenase 12 
TM4SF8 NM_005724 Tetraspanin 3 
CCNA2 NM_001237 Cyclin A2/cell cycle 
LAP3 NM_015907 Peptidase 
POLR2F NM_021974 Polymerase (RNA) II (DNA directed) polypeptide F 
RAD9B NM_152442 RAD9 homolog B (S. cerevisiae)/DNA replication 
DYRK1A NM_101395 Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A 
PCNA NM_002592 Proliferating cell nuclear antigen 
PCP4 NM_006198 Purkinje cell protein 4 
ZNF800 NM_176814 Unkown 
PELO NM_015946 Pelota homolog (Drosophila) 
DPH2L2 NM_001384 DPH2 homolog (S. cerevisiae) 
RFXAP NM_000538 Regulatory factor X-associated protein 
CLDN12 NM_012129 Calcium-independent cell-cell adhesion 
PIAS2 NM_004671 Protein inhibitor of activated STAT, 2 
ELAC1 NM_018696 ElaC homolog 1 (E. coli)/trna processing 
RDH10 NM_172037 Retinol dehydrogenase 10 (all-trans) 
   Genes Repressed by E2 
 
PXMP4 NM_007238 Peroxisomal membrane protein 4, 24kDa 
HBD NM_000519 Hemoglobin, beta /// hemoglobin, delta 
MAPK4 NM_002747 Mitogen-activated protein kinase 4 
ITPKB NM_002221 Inositol 1,4,5-trisphosphate 3-kinase B 
MXD3 NM_031300 MAX dimerization protein 3 
MGC15882 NM_032884 C1orf94 
LMOD1 NM_012134 Leiomodin 1 (smooth muscle) 
CD9 NM_001769 CD9 molecule/cell adhesion 
a Comparative analysis of ChIP-chip data and expression analysis following 12hr E2-stimulation  of MCF-7 cells 
allowed for the identification of p/CIP/CARM1 regulated genes. 
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possible mechanism of recruitment for the p/CIP/CARM1 complex to the Jak2 promoter. 
We found that the p/CIP/CARM1 complex binds in a ligand-dependent manner to the 
Jak2 promoter (Figure 2-6B). Importantly, we also determined that the ER binds Jak2 in 
response to ligand (Figure 2-6B). The presence of both the p/CIP/CARM1complex and 
the ER at the same region of the promoter suggests that E2-dependent complex 
recruitment to the Jak2 promoter is mediated through its interaction with the ERE-
associated ER. This finding is consistent with the putative status of Jak2 as one of the 59 
high-confidence ER targets. 
To determine whether the E2-dependent assembly of a p/CIP/CARM1 complex 
impacts the chromatin marks at the Jak2 promoter, ChIP analysis was performed using 
antibodies corresponding to histone modifications associated with transcriptional status; 
histone H3 lysine 4 trimethylation (H3K4me3) and acetylation of histone H3 at Lysines 9 
and 14 (H3Ac) are modifications generally indicative of transcriptionally active 
chromatin structure [46,47]. In addition, CARM1 is known to asymmetrically 
dimethylate arginine 17 on histone H3 (H3R17me2), a mark that is also associated with 
transcriptional activation [48]. 
E2-dependent changes in histone modifications were observed at the Jak2 promoter. 
In response to treatment, there was a modest increase in acetylation of H3K9 and H3K14 
(H3K9/14ac) (Figure 2-6C) and a statistically significant enrichment in dimethylation of 
H3R17 (Figure 2-6D), consistent with recruitment of a functional p/CIP/CARM1 
complex. Trimethylation of H3K4 remained unchanged by E2 treatment (Figure 2-6C), 
perhaps suggestive of a transcriptionally permissive but not fully active gene state, in 
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Figure 2-5 Functional classification of p/CIP/CARM1 target gene promoters. 
(A) Schematic Ingenuity pathway analysis indicates (A) that cancer is one of the diseases most 
commonly associated with the p/CIP/CARM1 target genes and (B) that molecular and cellular 
functions associated with the gene set highlights cellular growth and proliferation as 
predominating. Adapted from © 2000-2011 Ingenuity Systems, Inc. All rights reserved. 
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agreement with the modest E2-dependent increases in mRNA observed (Figure 2-4B). To 
determine if the changes in histone modifications are dependent on the presence of p/CIP, 
quantitative ChIP analysis was performed on the Jak2 promoter following siRNA-
mediated gene silencing of p/CIP. p/CIP was present minimally on the promoter despite 
p/CIP depletion (Figure 2-7B), likely due to incomplete knockdown (Figure 2-7A). The 
level of p/CIP present on the promoter was increased in response to hormone (Figure 2-
7B). The functional effect of p/CIP depletion was determined by ChIP assay evaluating 
the presence of the CARM1-dependent histone modification H3R17me2 in response to 
E2. As a chromatin mark associated with transcriptional activation, in the absence of 
p/CIP [and complex] recruitment, E2-dependent dimethylation of R17 on histone H3 was 
reduced (Figure 2-7B), indicating that p/CIP is likely required for recruitment of 
CARM1, and its subsequent methyltransferase activity. 
To further our understanding of the role that the p/CIP/CARM1 complex plays in 
regulating Jak2, we assessed its E2-dependent expression in the absence of p/CIP or 
CARM1. When a control siRNA was used, we saw a statistically significant induction of 
Jak2 expression, based on realtime PCR, after 12 and 24 h of E2 treatment. However, 
when p/CIP was downregulated using siRNA, this effect was diminished (Figure 2-7C). 
A similar experiment was performed following CARM1 knockdown and, although the 
knockdown was not complete, there was a more dramatic loss of E2-dependent Jak2 
expression as compared to p/CIP knockdown (Figure 2-7D). Interestingly, when MCF7 
cells were treated with E2, we also observed an increase in Stat3 phosphorylation, 
indicative of E2-dependent JAK/STAT pathway activation. However, when either p/CIP 
or CARM1 was depleted, this effect was lost (Figure 2-7C & D). Collectively, these data 
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suggests that p/CIP and CARM1 are in part required for the E2-dependent regulation of 
Jak2 transcription and activation of the JAK/STAT signaling pathway in MCF7 cells. 
 
2.3 Discussion 
In the present study, we identified E2-dependent target genes for the p/CIP/CARM1 
coregulatory complex. We then determined the transcriptional status of those genes 
following 12 h E2 treatment, and compared the lists with known ER binding sites in an 
attempt to clarify a mechanism for complex recruitment and subsequent gene regulation. 
Global characterization of p/CIP (SRC-3) binding sites conducted by Lanz et al. 
identified 12,294 E2-dependent targets using ChIP-Seq, 5512 of which were distinct from 
those found using vehicle stimulation [49]. Many of these sites overlap with previously 
identified ER binding regions, and, in accordance with accumulating genomic analysis 
indicating that the majority of ER binding sites are located in regions far upstream of the 
TSS, only a minority (~3%) of E2-dependent p/CIP binding is suggested to occur within 
500 bp of the TSS. The level of CARM1 activity (as assayed by its methylation of 
H3R17 and/or p/CIP) across the genome also appears to cluster predominantly at a 
distance from promoters [50]. These observations of a limited set of proximal promoter 
binding sites for p/CIP, and minimal CARM1 methylation activity at promoter elements 
correspond with the relatively small number of promoters we identified as interacting 
with the p/CIP/CARM1 complex, and is also consistent with proximal ER binding events 
previously identified using the 1 kb promoter-specific ChIP-DSL approach [43]. 
Although now largely superseded by ChiP-Seq, ChIP-DSL is a highly sensitive assay   
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Figure 2-6 Characterizing E2-dependent histone modifications to JAK2 proximal 
promoter 
(A) Schematic representation of the JAK2 1kb proximal promoter, highlighting region used for 
ChIP analysis. (B) Control and 17β-estradiol stimulated MCF-7 cells were cross-linked with 1% 
formaldehyde, and ChIP or sequential ChIP-reChIP was performed using the indicated 
antibodies, followed by qPCR. ChIPs were performed in triplicate, standardized to IgG, and 
shown as percentage of Input.  Statistical significance was determined using Student’s t-test and 
is indicated by * (p<0.05). (C-D) ChIP-qPCR analysis of JAK2 promoter following E2 treatment. 
ChIPs were performed in duplicate (H3K9/k14ac, H3K4me3) or triplicate (H3R17me2) using 
indicated antibodies, quantitated with real-time PCR, standardized to IgG control and shown as 
percentage of Input. Statistical significance was determined using Student’s t-test and is indicated 
by * (p<0.05). 
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which eliminates some of the biases introduced by more conventional ChIP-on-chip 
whole-genome approaches. In ChIP-DSL, the immunoprecipitated genomic DNA is used 
only as a template to mediate annealing and ligation of aligned oligonucleotide pairs. 
After annealing, the biotinylated DNA is then selected using streptavidin Sepharose and 
Taq ligase is used to ligate oligonucleotides positioned directly adjacent to each other, 
creating complete amplicons, which are hybridized to a 20,000 gene promoter array. A 
limitation of this approach is that analysis is restricted to those promoters found on the 
array, which contain 1 kb of upstream regulatory sequence. Studies have shown that the 
majority of ER binding sites are found more distal than the proximal promoter. 
Nevertheless, promoter proximal interactions do occur in response to E2 and this 
interaction can have transcriptional consequences. Furthermore, our study does not 
examine ER binding directly, but rather focuses on occupancy of p/CIP/CARM1 in 
response to E2. Thus, it would theoretically include those targets that are targeted to 
promoter regions by E2 independent of direct DNA binding, and possibly via enhancer–
promoter interactions. 
A major advantage of this approach is that we identified 204 promoter-proximal 
interaction sites for the p/CIP/CARM1 complex, eliminating the complicated process of 
assigning responsive genes to distant binding sites, and instead were able to directly 
correlate complex interaction with transcriptional effect. Previous microarray studies with 
E2-stimulation can be broadly categorized based on the length of hormone treatment. 
There is an observable difference in the pattern of expression change, such that at early 
time points (<6 h) more genes are upregulated and more variation is evident between 
time points, while at later time points (>12 h) there is a more stable pattern of expression 
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change and the majority of genes are downregulated [33,44]. We showed that after 12 h 
of stimulation with E2, approximately 20% of p/CIP/CARM1 complex target genes 
identified by ChIP-DSL were transcriptionally altered (16.2% upregulated and 3.9% 
downregulated). The relatively small number of transcriptionally changed target genes 
after 12 h implies that proximal recruitment of the p/CIP/CARM1 complex is not 
predictive of E2-dependent gene expression at this late time point. However, among those 
targets that are transcriptionally altered, the complex plays a preferential role in 
activation, consistent with the role of p/CIP as a coactivator. While the changes in target 
gene expression that we observed were modest, we do observe notable changes in 
chromatin modifications, suggesting that E2 may facilitate crosstalk. 
Direct comparison of target gene promoters in our study with known genomic ER 
binding sites in MCF-7 cells [under equivalent E2- stimulation conditions] [33,34] 
identified 59/204 (29%) p/CIP/CARM1 complex targets as putative high-confidence ER 
binding targets. Therefore, it seems likely that the p/CIP/CARM1 complex is recruited to 
this subset of E2-responsive promoters via the ER. We also identified a trend in which 
binding motifs for transcription factors known to facilitate ER recruitment were enriched 
among p/CIP/CARM1 complex target promoter sequences. While Sp1, C/EBP, Oct, 
FoxA1, and AP-1 motifs have previously been shown to be enriched, in addition to 
EREs, in the sequences surrounding ER binding events on a genome-wide scale 
[33,42,50], there has not previously been much discussion related to the proximal 
promoter region or when considering recruitment of an E2-regulated complex. Neither 
the predicted ER-binding state nor the transcriptional status of complex target genes after 
12 h E2 treatment was predictive of enrichment of transcription factor binding motifs   
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Figure 2-7 p/CIP/CARM1 mediated E2-dependent regulation of JAK2 
(A) Representative Western blot showing 72hr siRNA depletion of p/CIP in MCF7 cells. (B) 
ChIPs were performed in triplicate at JAK2 promoter regions using indicated antibodies, 
quantitated by real-time PCR, standardized to IgG control and shown as a percentage of Input. 
Data is expressed as means and standard error of the mean from triplicate experiments. (C-D) 
Analysis of E2-dependent JAK2 transcription (top) and STAT3 activation (bottom) with siRNA-
mediated depletion of (C) p/CIP or (D) CARM1. (Top) Realtime RT-PCR analysis of  JAK2 was 
performed following 12 and 24hr exposure to hormone, and data is expressed as the mean and 
standard error of the mean from triplicate experiments, performed independently. Student’s t-test 
was used to compare E2-induced expression changes and statistically significant differences from 
control samples are indicated. (Bottom) Representative Western blot showing knockdown 
efficiency and STAT3 activation in MCF7 cells following E2 treatment. 
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studied, and so, consensus mechanisms for differential transcriptional responses as 
implied by the recruitment of the ER could not be inferred. 
Several of the targets identified are components of the canonical JAK/STAT 
signaling pathway. This pathway mediates the activity of a wide variety of cytokines and 
growth factors [51]. JAK2 is a central component of the pathway and is responsible for 
phosphorylation and activation of the STAT family of proteins, which normally reside in 
the cytoplasm and, upon activation, translocate to the nucleus and bind to specific target 
genes involved in cell proliferation and survival [51]. JAK2 or STAT5 null mice display 
phenotypes remarkably similar to the ERα and p/CIP knockout animals including defects 
in mammary gland cell proliferation and apoptosis [52,53]. Importantly, overexpression 
or constitutive activation of STAT3 and 5 proteins has been described in many types of 
cancers [54] and promote the occurrence of sporadic mammary cancers in mice [45,55–
57]. In proliferating ER-positive tumor cells, E2 is known to stimulate phosphorylation 
and activation of STAT3 and 5, although the mechanism has not been fully elucidated 
[58–60]. The PIAS family, most notably recognized for their role as coregulators for 
STAT proteins, is also of interest as PIAS1 has been shown to sumoylate p/CIP [and 
other SRCs], affecting activity and stability in steroid-receptor signaling pathways in 
MCF-7 cells [20]. Collectively, these findings suggest that ER signaling and the 
JAK/STAT pathway may cooperate in the regulation of mechanisms implicated in 
mammary cancers. This cooperation may be mediated, at least in part, through the 
p/CIP/CARM1 complex. 
We observed recruitment of the p/CIP/CARM1 complex to the 1 kb promoter of Jak2 
in response to E2, with a transcriptional upregulation after 12 and 24 h, but no significant 
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effect on protein levels with E2 stimulation. Analysis of histone modifications to the 
proximal 1 kb promoter revealed an unclear pattern that was predictive neither of 
transcriptional activation nor repression. A modest increase in acetylation of histone H3 
at K9 and K14 was observed at a region approximately 1 kb upstream of the Jak2 TSS in 
response to E2, which coincides with p/CIP/CARM1 complex recruitment, suggestive of 
a transcriptionally active gene. In contrast, there was a lack of discernible change in 
H3K4me3 in response to E2 at the same promoter region, a modification that would be 
expected to be present near the TSS of an actively transcribed gene [61,62]. We suggest 
that these changes reflect a promoter that is not necessarily in line with a fully 
transcriptionally active state but may instead be permissive, poised for more robust 
transcriptional activation, in a process that may require additional signals. 
Our study of chromatin modifications was focused to a single time point for E2 
treatment. This is based on previous studies showing maximal p/CIP/CARM1 
recruitment to the pS2 promoter 45 min after the addition of hormone [16]. Importantly, a 
statistically significant E2- dependent increase in H3R17me2 was evident, corresponding 
with the region of p/CIP/CARM1 recruitment, suggesting the complex is functional on 
the Jak2 promoter. Reinforcing this idea, we noted that following depletion of p/CIP, E2-
dependent H3R17me2 of the Jak2 promoter was greatly reduced in addition to an 
observable loss of p/CIP recruitment. Finally, siRNA mediated depletion of p/CIP 
resulted in a reduction in E2-induced transcription of Jak2, with residual E2- 
responsiveness likely due to functional redundancy between SRC family members. 
However, depletion of CARM1 caused a more dramatic loss in E2-dependent Jak2 
transcription, suggesting that its enzymatic activity is in fact important for the observed 
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regulation by the p/CIP/CARM1 complex. CARM1 activity has previously been 
associated with the regulation of a subset of the ER cistrome [50], and herein we provide 
a specific example of its E2-dependent recruitment, as part of an active coregulatory 
complex, to the Jak2 promoter. We also observed an increase in phosphorylated STAT3, 
indicative of activation of the JAK/ STAT signaling pathway. While this activation is not 
necessarily dependent on Jak2 transcriptional upregulation, this effect was lost following 
siRNA-mediated silencing of p/CIP or CARM1. 
Collectively, while the changes in E2-dependent H3R17 dimethylation are indicative 
of active Jak2 transcription, the other chromatin marks we examined, as well as the 
modest response at the RNA and protein levels, were inconsistent with a fully 
transcriptionally active promoter. We suggest that an additional signal may be required 
for a more robust transcriptional response of the Jak2 gene. In addition, despite the 
changes in expression of select genes, the majority of complex targets did not exhibit a 
widespread transcriptional response to 12 h E2 treatment, ultimately suggesting that E2 
may cause a general “rewiring” of specific signaling pathways, through recruitment of 
the p/CIP/CARM1 complex, so that many essential genes become “poised” for 
transcription. 
2.4 Materials & Methods 
2.4.1 Plasmids, antibodies, and reagents 
A complete list of primers used can be found in Table B-3 in Appendix B. 
Antibodies used in this study are listed in Table B-4 in Appendix B. All of the antibodies 
used for these studies are commercial antibodies, with the exception of the p/CIP 
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antibody. The method by which this antibody was generated, purified, and tested has 
been previously described [4]. 17β-Estradiol (water soluble) was purchased from Wisent. 
All siRNA used was purchased from Dharmacon. 
2.4.2 Western Blotting 
Cells were grown in phenol red-free DMEM, supplemented with charcoal 
stripped FBS and antibiotics, and stimulated with 10−7 M E2 for various time periods as 
indicated. Cells were washed twice in phosphate buffered saline (PBS), harvested and 
lysed in RIPA lysis buffer (~150 µl/60 mm plate) consisting of 50 mM Tris (pH 8.0), 150 
mM NaCl, and 1% NP-40, 0.1% SDS and protease inhibitor cocktail. Extracts were 
centrifuged for 10 min at 14,000 rpm at 4 °C and the soluble fractions were retained. 
Samples were normalized for protein content and were separated by SDS-PAGE, 
transferred to nitrocellulose or PVDF membrane and blocked overnight in PBS 
containing 0.1% TWEEN-20 and 5% nonfat dried milk. The appropriate antibodies were 
then diluted in blocking buffer and the membrane was probed for 2 h at room temperature 
with rocking, followed by incubation with secondary antibody for 1 h. Proteins were 
detected using ECL according to the manufacturer's recommendations (Amersham). 
2.4.3 RNA isolation and real-time PCR 
Total cellular RNA was isolated using RNeasy kit (Qiagen). The quality and 
quantity of RNA were evaluated by measuring OD 260/ 280. For real-time PCR analysis, 
0.2 µg of RNA was reverse-transcribed with TaqMan reverse transcriptase (Applied 
Biosystems) using random hexamers to generate cDNA. All amplicons were detected 
using the 5′ nuclease (Taqman) assay with 5′ labeled probes. Probes were already 
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predesigned and quality tested (Applied Biosystems). Reactions were performed 
according to the manufacturer's recommendations (Applied Biosystems) and were run in 
replicates of two, in a 96-well format. Each reaction included 18S RNA as a control for 
normalization, and reactions lacking cDNA served as negative controls. Two independent 
experiments were performed for each gene following treatment with E2, and a mean 
value was obtained and compared to the mean expression level of each gene from 
untreated cells. Applied Biosystems 7500 Real Time PCR System software was used to 
identify cycle threshold (Ct) for each reaction. 
 
2.4.4 RNA microarray analysis 
Total RNA was extracted from MCF-7 cells treated with 10 nM E2 for 12 h and 
from control, untreated cells. Independent biological triplicates were performed for each 
treatment, including control samples. cDNA was prepared from control and treated 
samples, labeled and hybridized to HgU133A+2 human affymetrix DNA microarray. 
Hybridization, washing, scanning and analysis of genechips were performed at the 
University of Western Ontario, London Regional Genomics Centre (London, Ontario, 
Canada). An average intensity of each E2-treated sample was compared to the average 
intensity for control non-treated samples. Three biological replicates for each array were 
processed and the data was transformed using Robust Multi-Array normalization and 
values below 0.01 were set to 0.01. Each measurement was normalized by dividing all 
measurements in that sample by the 50th percentile. Ratios were then calculated for all 
samples against the median of the control samples. A student t-test statistical analysis 
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was conducted and false positives were reduced using Benjamini and Hochberg false 
discovery rate. 
2.4.5 Chromatin immunoprecipitation assay 
 MCF-7 cells were cross-linked with 1% formaldehyde at room temperature for 5 
min. Cross-linking was quenched by immediately washing cells twice with ice-cold PBS 
and harvesting in PBS containing PMSF. Cell pellets were lysed in 0.2 ml of cell lysis 
buffer (50 mM Tris-HCl [pH 8.1], 10 mM EDTA, 1% SDS, and protease inhibitors) and 
incubated on ice for 10 min. Lysates were sonicated to yield DNA fragments ranging in 
size from 300- to 1000-bp. Approximately 450µg of the cross-linked, sheared chromatin 
solution was used for immunoprecipitation. A small portion of each IP was saved as input 
DNA (5%). Supernatants were diluted 10-fold in dilution buffer (20 mM Tris-HCl [pH 
8.1], 1% Triton X-100, 2 mM EDTA, 150 mM NaCl, and protease inhibitors) and 
immunoprecipitated using a protein A-Sepharose slurry or with MagnaChIP Protein A 
magnetic beads.  
 When using the Protein A-Sepharose slurry, lysates were precleared with 50 µl of 
50% slurry protein A-Sepharose containing 2.5 µg of sheared salmon sperm DNA for 2 h 
at 4°C. Immunoprecipitation was performed overnight at 4°C with 1.5-4 µg of the 
antibodies. 50 µl of protein A-Sepharose containing 2.5 µg of salmon sperm DNA per ml 
was added to the solution and incubated for 1 h at 4 °C. Magnetic beads were washed 
using PBS with 0.1% Tween-20, incubated with the relevant antibodies for 2.5hrs at 4 
°C, and rewashed prior to immunoprecipitation overnight at 4°C. The beads were washed 
one time each with wash buffer I (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM 
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Tris-HCl, 150mM NaCl), wash buffer II (0.1% SDS, 1% Triton X-100, 2mM EDTA, 
20mM Tris-HCl, 500mM NaCl), wash buffer III (0.25 M LiCl; 1% NP-40; 1% Na-
Deoxycholate; 1 mM EDTA; 10 mM TrisHCl) and twice with TE buffer. 
Immunoprecipitated material was extracted twice with 150 µl elution buffer (1% SDS-0.1 
M NaHCO3). If sequential ChIP was conducted, eluted samples were re-
Immunoprecipitated overnight at 4°C with 1.5-4 µg of secondary antibodies. Washes and 
elution steps were repeated. NaCl was added to the final 150 µl eluate to a concentration 
of 200 mM and the cross-linking was reversed by heating at 65 °C overnight. DNA was 
purified using Qiagen PCR purification spin columns.  
 For analysis by conventional PCR, conditions were as follows: initial denaturing 
cycle of at 94 °C for 3 min, followed by 40 cycles of 94 °C for 30 sec, ~57 °C for 30 sec 
and 72 °C for 45sec, and a final elongation step of 72 °C for 10 min. For experiments 
involving E2-stimulation, MCF-7 cells were plated to approximately 90% confluence and 
treated with 10-7M E2 for 45 min prior to ChIP analysis.  
For some experiments, DNA isolated from ChIP experiments was subjected to 
quantitation by real time PCR using Brilliant SYBR green master mix (Stratagene; 
600548). Primers were identified using the Primer Express program (Stratagene) and 
tested to establish optimum reaction conditions. Reactions were performed in a 25ul 
volume according to manufacturer’s recommendations. The reaction was carried out and 
measured using Mx3000P realtime instrument. Standard curves were generated using 
total input DNA (copy number range: 8X105 to 8X101). The IP and IgG DNA copy 
number was calculated by extrapolating their respective Ct value from the standard curve. 
The nonimmune IgG copy number was subtracted from IP DNA copy number. The 
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resulting IP copy number was initially normalized against the total input DNA by 
dividing the IP by input. The average copy number with E2-treated IPs were then 
standardized to untreated control IPs, and recruitment represented as a fold-change with 
E2-treatment. All measurements were done in duplicate and an average Ct value was 
used to calculate copy number. Two independent realtime reactions were done for each 
experiment.  
2.4.6 ChIP-DSL assay 
Chromatin immunoprecipitation coupled to DNA selection and Ligation (ChIP-
DSL) was used to assess global promoter occupancy by p/CIP/CARM1. MCF-7 cells 
were cross-linked with formaldehyde and subjected to standard sequential ChIP–reChIP 
assay using affinity purified anti-p/CIP and anti-CARM1 antibodies. The procedure for 
oligonucleotide annealing, solid phase selection ligation and PCR amplification were 
performed exactly as described (Aviva Systems Biology; H20K, Cat# AK-0504). The 
antibody-enriched DNA and the total input were biotinylated followed by annealing to 
the 40mer oligonucleotide pool. The DNA–oligonucleotide complexes are then selected 
by binding to streptavidin-conjugated magnetic beads, while the non-annealed 
oligonucleotides are washed away. Correctly paired 40mers are then ligated to form the 
corresponding 80mer which is flanked by both universal primer annealing sites (T3 and 
T7) giving rise to a complete amplicon. A PCR reaction was then conducted on the 
amplicons using fluorescently labeled T7 and regular T3 primers. Total input DNA was 
PCR amplified using Cy5 (green) labeled T7 primer and the immunoprecipitated (IP) 
sample was amplified using Cy3 (red) labeled T7 primer. The PCR products are co-
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hybridized to the 80mer array (Hu20K) to derive an enrichment ratio for each target. 
After hybridization and washing, array slides were scanned on a One Virtek (Bio-Rad) 
Chip Reader, and the ArrayVision (v6.0) software package (London Regional Genomics 
Centre, London, Ontario, Canada) was used to quantify fluorescence intensity. The ChIP 
on chip intensity values were normalized using a Lowess curve, which was fit to the log 
intensity versus log-ratio plot and 20% of the data was used to calculate the Lowess fit at 
each point. Following normalization, a two-sided student's t-test was conducted where 
standard deviation of the replicates was used to calculate a p-value. Fold change was 
calculated for each gene using a mean value that was calculated from all three biological 
replicates. 
2.4.7 Ingenuity Pathway Analysis 
Ingenuity Pathways Systems (http://www.ingenuity.com) analysis was employed to 
group statistically significant genes. The 204 genes that bound p/CIP/CARM1 directly 
and were transcriptionally affected by E2 were considered for Functional Analysis to 
identify the biological functions and/or diseases that were most significant to the data set. 
A right‐ tailed Fisher's exact test was used to calculate a p‐value determining the 
probability that each biological function and/or disease assigned to that data set is due to 
chance alone. 
2.4.8 Promoter Enrichment Analysis 
Promoter sequences were identified using Gene2Promoter within the Genomatix 
Suite (www.genomatix.de). Input was in the form of gene accession numbers, and 
comparison with transcripts that have been mapped to the ElDorado genome yielded 
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mapped sequence results and extracted promoters. A defined 1000bp upstream of the 
mapped transcriptional start sites were selected for further transcription factor binding 
site analysis. To search for enriched consenus motifs within ElDorado extracted promoter 
sequences the BIOBASE Knowledge Library was used, making use of MATCH software 
and the Transfac database. Searches were performed with the best supported promoters 
using the vertebrate non redundant (minFP) profile. Background frequencies were 
determined using control set of human housekeeping gene promoters. Optimized matrix 
cutoffs and search window positions were used. Significant matrices were found with p-
value<0.001 and Yes/No>1.2. 
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  Chapter 3
 Whole Genome Analysis of CARM1 in wildtype and 3
CARM1-knockout Mouse Embryonic Fibroblasts 
3.1 Introduction 
 Arginine methylation is a prevalent post-translational modification, found on both 
nuclear and cytoplasmic proteins, that has been implicated in the regulation of 
transcription, signal transduction, RNA processing, and DNA repair  [1-4]. Additionally, 
defects in arginine methylation are known to be involved in several disease processes 
such as cancer  [4-6]. 
 The family of proteins responsible for arginine methylation is collectively known as 
protein arginine methyltransferases (PRMTs). Coactivator-associated Arginine 
Methyltransferase 1 (CARM1), also known as PRMT4, is a Type I PRMT that catalyzes 
the formation of asymmetrically dimethylated arginines (aDMA) through a 
monomethylated intermediate  [7]. CARM1 is unique among the PRMTs in that it 
appears to recognize substrates containing a PGM motif (proline, glycine, methionine), 
rather than the more common GAR motif recognized by other PRMT family members  
[1,2,7,8]. 
CARM1 was the first of the PRMTs to be shown to function as a transcriptional 
coactivator [1], based on its ability to interact with the p160 coactivator GRIP-1 (also 
known as SRC2, NCoA2)  [1]. It has since been shown to interact with the two other 
members of the p160 family, SRC1 and SRC3 (p/CIP)  [1]. CARM1 can methylate both 
histone and non-histone proteins, and its ability to synergistically enhance transcription of 
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steroid-hormone-regulated genes through its methylation of other coregulators such as 
p300, p160 family member(s), and of histone H3 has been extensively characterized  [9-
12]. 
CARM1 has been shown to regulate a wide variety of transcriptionally relevant 
target genes, in cell cycle control in addition to those involved in hormone-dependent 
signaling. For example, in response to DNA damage CARM1 methylates the p300 KIX 
domain. This promotes recruitment of BRCA1 by p300 to the p53-responsive promoter 
of p21 and promotes p21 transcription and increased expression  [3]. Additionally, 
CARM1 is recruited to the promoter of cyclin E1 (CCNE1) in an E2F-dependent manner, 
where it functions as a positive regulator of transcription, by methylating histone H3 at 
arginines R17 and R26  [13].  Deletion of CARM1 in mice results in embryos that are 
small in size, and die late in development or shortly after birth  [14]. CARM1 null mouse 
embryonic fibroblasts (MEFs), isolated from E12.5 embryos, do not support the 
methylation of CARM1 substrates, including histone H3, p300 and PABP1, and are 
defective in NR-dependent signalling  [14]. Additionally, NF-kB dependent gene 
expression, important for cellular events such as apoptosis, cell proliferation and 
differentiation, is also impaired in CARM1-null MEFs  [14]. CARM1 has been shown to 
form a complex with p300 and NF-kB in vivo, directly interacting with NF-kB, and 
enhancing its promoter-specific recruitment. CARM1 also interacts with β-catenin and 
positively regulates β-catenin-mediated gene expression, indicated by H3R17 
methylation  [15]. CARM1 can also covalently modify components of the core 
transcriptional machinery. CARM1 methylates the C-terminal domain of RNA 
Polymerase II at a single arginine residue (R1810), creating a docking site for a tudor-
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domain containing effector molecule (TDRD3) and promoting transcription  [16]. PAF1c, 
part of the transcription elongation complex, interacts with the CARM1-specific 
H3R17me2 mark, and affects transcription of CARM1-regulated, estrogen responsive 
genes, indicating that PAF1c may act as an arginine methylation effector  [17]. 
CARM1 has also been shown to interact with several oncogenic transcriptional 
regulators, suggesting that CARM1 plays a role in cancer. CARM1 levels have been 
found to be elevated in aggressive breast tumours  [18,19], and in conjunction with 
elevated SRC3 plays a role in ERα-­‐‑dependent breast cancer cell differentiation and 
proliferation  [20,21]. Recent studies using large panels of invasive breast cancer samples 
suggest that CARM1 has an oncogenic effect in breast cancer, and that its expression is a 
predictor of diminished survival, and of poor disease-free survival  [18,19]. CARM1 is 
also overexpressed in androgen-independent prostate carcinomas, and in colorectal 
cancers  [18,19,22]. 
The majority of CARM1 studies have been conducted in cancer cell lines, and 
evaluation of the role CARM1 plays in gene regulation has been primarily focused on its 
ability to interact with and regulate the function of specific transcriptional regulators with 
little consideration given to the recruitment of CARM1 on a genome-wide scale, 
unbiased by association with binding partners.  
In this study, we use a ChIP-Seq approach in conjunction with expression 
microarray to assess the role of CARM1 in genome occupancy and global gene 
regulation. We conducted our examination in CARM1 wildtype and knockout mouse 
embryonic fibroblasts (MEFs), a system unaffected by genomic instability in which the 
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relevance of direct CARM1-dependent gene regulation can be studied. The absence of 
any extrinsic signal or disease context is quite novel and allows for a broader 
understanding of CARM1 action, without limiting its functionality to specialized cellular 
programs or particular disease states. Our characterization of binding events suggests a 
role for CARM1 in transcriptional elongation, and implicates the transcription factor 
PAX1 as potential mechanism through which CARM1 can be recruited to the genome. 
While our findings suggest that direct genomic recruitment of CARM1 is not critical for 
its transcriptional and functional effect(s) in an un-induced system, we note a critical 
regulatory role for CARM1 in cellular growth and proliferation, showing that in the 
absence of CARM1, the expression of many cell cycle regulators is dramatically altered 
and cells become sensitized to additional stressors.  
3.2 Results 
3.2.1 Analyzing genome-wide CARM1 recruitment 
To identify global genomic interaction sites for CARM1, we performed ChIP-Seq 
in CARM1+/+ MEFs (Figure 3-1A). Approximately 40 million sequenced reads were 
obtained and processed to eliminate corrupt, short, and/or highly repetitive sequences, 
before being aligned to the mouse genome (MM9). Based on this alignment and using an 
FDR of 0.001, 7022 CARM1-dependent peaks were identified. These peaks were 
subsequently filtered using the Mann-Whitney (MW) U test as an intra-sample statistic to 
remove false peaks based on strand separation, thereby refining the list to include only 
high confidence CARM1-enriched regions. Applying a MW p-value of 0.05, we 
identified 432 enriched regions. Several of these regions were validated using 
conventional ChIP and ChIP-qPCR (Figure 3-2 and Figure C-1). We determined that   
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Figure 3-1 Genome-wide identification of CARM1 recruitment sites in MEFs 
(A) ChIP-Seq was performed to identify global genomic CARM1 interaction sites. Sequenced 
reads were aligned to the mouse genome (MM9) and peaks were called using Partek Genomics 
Suite. (B) Pie chart indicating the genomic distribution of FDR0.001 CARM1 peaks. Promoter 
was defined as 5kb upstream & 1kb downstream of TSS. (C) Pie chart indicating the genomic 
distribution of subset of FDR0.001 CARM1 peaks identified as significantly enriched CARM1 
binding regions by Mann-Whitney U test (p < 0.05). Promoter was defined as 5kb upstream & 
1kb downstream of TSS. (D) Association between CARM1 and PAF1c. CARM1 was 
immunoprecipitated from CARM1+/+ MEFs; immunocomplexes were separated by SDS-PAGE 
and probed with either αPaf1c or αCARM1 antibodies (n=2).  
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CARM1 binding is fairly frequent and occurs on average every 378 kb in the mouse 
genome. However, Mann-Whitney enriched regions of CARM1 binding events were 
more sparse, occurring every 6,174kb. The incidence of CARM1-interacting sites and/or 
enriched regions showed weak positive correlation with chromosome length (Figure C-
1). 
When CARM1 enriched regions were annotated to neighboring genes, 153 genes 
were identified. Interestingly, in some regions, more than one CARM1-binding event can 
be associated with the same gene (Figure C-1). This pattern is most prevalent on 
chromosome 8 and X (Figure C-1). However, the functional significance of multiple 
binding sites is currently unclear. 
When we considered the genomic distribution of all 7022 CARM1 binding 
events, or of the smaller cohort of 432 MW-enriched regions, we found that the pattern of 
peaks and enriched regions is very similar (Figure 3-1B & C). The majority of binding 
(66-70%) occurs in intergenic regions, with the remaining 30-34% associated with 
intragenic elements, which includes the promoter region, 3’- and 5’-UTRs, and coding 
sequence (CDS). Of the intragenic regions, 17-18% of identified CARM1-interacting 
sites were found to be promoter-proximal (defined as 5kb upstream and 1kb downstream 
of TSS), with a further 16% of binding in the 5’UTR, indicative of a regulatory role for 
CARM recruitment. Contrary to our initial expectations, the majority of CARM1-bound 
intragenic sites were found to occur within the CDS. These binding events suggest a 
potential role for CARM1 in alternative splicing, a function in which CARM1 has 
already been implicated through its methylation of several splicing factors  [2]. 
Alternately, the predominance of CDS binding sites could also be indicative of 
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participation by CARM1 in transcriptional elongation. To assess this possibility, we 
performed immunoprecipitation experiments in wildtype MEFs using a CARM1 
antibody. Subsequent probing for the elongation-associated RNA polymerase-associated 
factor 1 complex (Paf1C) revealed that CARM1 can interact directly with Paf1c (Figure 
3-1D), suggesting a potential role for CARM1 in transcriptional elongation. 
 
3.2.2 Elucidating the mechanism of CARM1 recruitment 
In an attempt to understand the mechanism(s) through which CARM1 is recruited 
to the chromatin in the absence of an extrinsic signal, enriched transcription factor (TF) 
binding motifs within all 7022 CARM1 binding events were identified. The most 
enriched TF consensus motifs were Hunchback (PAX1), ZNF354C, YY1, Gfi, and MZF1 
(Figure 3-3A), all of which have been implicated in transcriptional regulation during 
development and/ or oncogenesis. Further assessment allowed for the identification of an 
enriched de novo motif among peaks (Figure 3-3B). Notably, the motif discovered de 
novo bears striking similarity to the PAX1 consensus motif, which was identified as the 
most significantly enriched among CARM1 peaks. This concordance suggests that this 
may be a preferred TF through which CARM1 is recruited to the genome. 
Comparison of CARM1 peaks and individual TF motif occurrences across whole 
chromosomes revealed an expected correlation wherein the top 5 enriched TF motifs 
frequently coincide with the MW enriched, high-confidence binding regions for CARM1. 
When specifically comparing CARM1 MW-enriched binding regions with the locations 
of PAX1 motifs, we observed that high-confidence CARM1 regions corresponded with   
104 
 
 
 
Figure 3-2 Quantitative ChIP analysis validating CARM1 occupancy at sites 
identified by ChIP-Seq 
CARM1 recruitment to Apbb1ip-, Ctnnd2-, Gm7120-, and Raet1d-proximal genomic locations 
was tested in CARM1+/+ MEFs using CARM1-/- MEFs as a negative control. CARM1 ChIPs were 
standardized to IgG control, and data is represented as mean percent of input and error bars 
represent standard error of the mean. 
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Figure 3-3 Transcription factor motif enrichment within CARM1 peaks identifies 
PAX1 as possible mechanism of CARM1 recruitment 
(A) Enriched JASPAR transcription factor binding motifs found among CARM1 peak sequences 
identified by ChIP-Seq.  (B) 14bp motif predicted using de novo motif discovery in Partek 
Genomics Suite. Height of each position indicates the importance of a base at a particular 
location. Different colors were used to represent different nucleic acids: G - yellow; T – red; C - 
blue; and A - green. (C) Bar graph contrasting the number of MW enriched regions of CARM1 
binding on each chromosome (grey) with the number of corresponding PAX1 consensus motifs 
(hatched). 
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PAX1 motifs on average 45% of the time (Figure 3-3C). A representative example of this 
trend on chromosome 14 is shown in Figure C-2.  
Several of the CARM1 enriched regions containing putative PAX1 binding sites 
were selected to assess the role of PAX1 in CARM1 genomic recruitment. Regions were 
randomly selected from different chromosomes, and in many cases represented different 
genomic contexts (ex. promoter-associated, within CDS, and/or intergenic). Quantitative 
ChIP analysis was performed in wildtype and CARM1 null MEFs to validate CARM1 
binding at these regions (Figure 3-4A). This analysis was repeated following siRNA-
mediated depletion of PAX1 in wildtype MEFs to determine if CARM1 recruitment is 
dependent on the presence of PAX1. When PAX1 was depleted (Figure C-3), there was a 
reduction in CARM1 recruitment at analyzed regions (Figure 3-4B), suggesting that 
PAX1 may facilitate the binding of CARM1 to a subset of genes.  
 
3.2.3 Identifying CARM1-dependent global transcriptional effects 
Gene expression profiling by microarray analysis was performed in both wildtype 
and knockout CARM1 MEFs to assess global transcriptional effects of CARM1. Gene 
expression profiles for CARM1-/- and CARM1+/+ MEFs were compared with an 
unadjusted p-value cutoff of 0.01. Using this approach, we identified 643 genes which 
were found to have a 2-fold or greater change in expression; 283 were upregulated, and 
360 downregulated in the absence of CARM1 (Figure 3-5A). The findings of the 
expression microarray were extensively validated, using both Western blotting and real-
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time RT-PCR analysis to confirm the expression of selected genes (data not shown and 
Figure 3-5B).  
In general, the expression changes in the absence of CARM1 were modest, with 
most up- or down-regulation falling within ±5-fold. The 10 genes showing the greatest 
increase and 10 genes showing the greatest decrease in expression in CARM1-/- MEFs as 
compared to CARM1+/+ MEFs are given in Table 3-1. Several of these genes have 
previously been implicated in a variety of cancers and other diseases, affecting cellular 
programs such as growth, proliferation, p53-mediated apoptosis, cellular migration, 
attachment, cell signalling, and drug metabolism. However, the range of distinct 
processes impacted by these CARM1-regulated genes implies that functional importance 
of CARM1 lies in its ability to act as a master regulator of numerous physiological 
pathways that can be coopted in disease states. 
 
3.2.4 Changes in gene expression regulated by genomic CARM1 
recruitment 
 To discern targets that may be directly regulated by CARM1 recruitment, 
expression microarray data was compared with the ChIP-Seq, so that CARM1 peaks 
could be associated with differentially expressed (DE) genes. Differentially expressed 
genes were also compared with the smaller list of MW enriched CARM1-binding 
regions. CARM1-interacting sites within varying distances of the TSS for differentially 
expressed genes were identified (Table 3-2). As previously discussed, more than one 
CARM1 peak can be associated with the same gene. This was notably evident when 
identifying genes directly-regulated by CARM1, and while 147 differentially expressed   
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Figure 3-4 PAX1-dependent CARM1 recruitment 
Quantitative ChIP analysis testing CARM1 occupancy at sites identified by ChIP-Seq that contain 
PAX1 TF motif. (A) Validation of CARM1 recruitment to noted genomic locations was tested in 
CARM1+/+ MEFs, using CARM1-/- MEFs as a negative control. (B) CARM1+/+ MEFs were 
transfected using either control siRNA, or an siRNA directed against PAX1, and qChIP analysis 
at the indicated regions was performed. CARM1 ChIPs were standardized to IgG control, and 
data is represented as mean percent of input and standard error of the mean. 
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Table 3-1 Most differentially expressed genes in CARM1-/- MEFs. 
Gene Symbol RefSeq ID Fold Change 
Aspn NM_025711 -136.352 
Postn NM_015784 -118.104 
Thbs2 NM_011581 -40.107 
Fam129a NM_022018 -33.4576 
Mmp3 NM_010809 -32.6422 
AW551984 NM_178737 -30.314 
Gas6 NM_019521 -27.245 
Dpt NM_019759 -26.9105 
Arhgdib NM_007486 -24.9759 
Plxdc2 ENSMUST00000028081 -24.1199 
Pappa2 NM_001085376 16.9961 
Cp NM_001042611 20.1459 
Tmem176b NM_023056 20.1924 
Tmem176a NM_025326 21.6729 
Anpep NM_008486 22.1114 
2610305D13Rik NM_145078 25.2344 
Prl2c3 NM_011118 25.6564 
Cyp1b1 NM_009994 25.7046 
Pde3b NM_011055 28.3394 
Peg3 NM_008817 34.6941 
 
Table 3-2 Differentially expressed CARM1-associated genes. 
 
 
# CARM1-associated genes % CARM1-dependent expression 
Total* Unique Up-regulated Down-regulated 
1kb 92 52 43 57 
5kb 112 58 46 54 
10kb 128 63 49 51 
50kb 340 147 43 57 
         *Total # genes counts the same gene(s) more than once if multiple CARM1 peaks are within the noted distance 
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genes were found to have one or more CARM1 peak(s) within 50kb, a total of 340 peaks 
could be associated with these genes. However, the presence of more than one CARM1 
binding event did not affect the degree to which genes were up- or down-regulated. Of 
the 147 unique DE genes, 43% were transcriptionally upregulated, and 57% 
downregulated (Figure 3-6A), proportions that are consistent with the overall trend of 
transcriptional changes following CARM1 loss (Figure 3-5A). 
 Only 5% of peaks were associated with differentially expressed genes when 
CARM1 binding occurred within 50kb of the TSS, and less than 2% if binding was more 
proximal [5kb to TSS], suggesting that direct genomic recruitment of CARM1 is not 
critical to its transcriptional effects in the absence of extrinsic signal.  
 
3.2.5 Functional consequences of CARM1-dependent global 
transcriptional changes 
Gene ontology (GO) analysis was performed to more fully characterize the 
relevance of CARM1-dependent global transcriptional changes. Enriched functional 
groups were reported if they had more than 2 genes represented and GO terms were 
grouped according to their relevance in biological processes, molecular functions, or with 
respect to cellular component. When GO analysis was conducted on CARM1-dependent 
differentially expressed genes, 2454 GO terms were identified. By comparison, when GO 
analysis was conducted on the subset of DE genes that had a peak or MW enriched region 
within 50kb of the TSS, the number of corresponding terms was substantially reduced 
(Figure 3-6B). This observation reinforces our suggestion that CARM1 genomic binding 
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events are most likely not required for CARM1-dependent transcriptional or functional 
consequences. 
Terms were initially ranked based on attribute score, with a higher score 
indicating processes that may be of particular importance to the data set, ostensibly those 
processes that are influenced most by CARM1. As expected, protein arginine methylation 
is notably affected by loss of CARM1, with associated methyltransferase processes 
corresponding to 7 of the 10 highest ranked GO terms. Steroid hormone signalling, and 
acetylation of histones were also ranked highly; corresponding with the most extensively 
characterized cellular functions of CARM1. Both of these functional changes have been 
extensively characterized in the literature, and were independently validated in our study 
[data not shown].  
 Taking an alternate approach, enrichment score was used to rank GO terms. A 
greater enrichment score suggested that genes in a given functional group were 
overrepresented among CARM1-regulated genes. The most prevalent molecular 
functions associated with the differentially regulated genes were transcription factor 
activity and protein binding, again corresponding with the known roles of CARM1. 
Among the associated biological processes, metabolic processes and growth were 
identified as two of the most represented functional categories (Figure 3-7A). Growth 
characteristics that were affected by the loss of CARM1 included cellular proliferation, 
cell cycle, cell shape and adhesion. Based on these findings we assessed differences in 
cellular proliferation between wildtype and CARM1 null MEFs. CARM1 null MEFs 
proliferated at a reduced rate when compared to wildtype (Figure 3-7B) and were also   
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Figure 3-5 Microarray expression analysis of global expression changes in the 
absence of CARM1 
(A) Proportion of differentially expressed genes in CARM1-/- as compared to CARM1+/+ MEFs. 
(B) Realtime RT-PCR analysis of selected differentially expressed genes (p/CIP, Jak2, Fgf10, 
p21, CARM1) in CARM1-/- and CARM1+/+ MEFs. Data is expressed as means and standard error 
of the mean from repeated experiments, performed independently (n=2 or 3). 
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Figure 3-6 Correlating direct genomic recruitment of CARM1 with changes in 
expression 
(A) Pie chart indicating the proportion of genes differentially expressed in CARM1 null MEFs as 
compared to wildtype, which have a CARM1 peak within 50kb of the TSS as identified by ChIP-
Seq. The percentage of these directly targeted, differentially expressed genes that are up- and 
down-regulated is also indicated. (B) Bar chart comparing the number of GO terms represented 
among genes differentially expressed (black bars) in the absence of CARM1, with those 
differentially expressed genes that have a CARM1 peak (grey bars) or MW enriched region 
(hatched bars) associated within 50kb. GO terms are subcategorized into biological processes, 
molecular functions, and cellular component.  
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shown to have reduced diameter and cell volume (Figure 3-7D).  
Expression microarray results implicated CARM1 in the regulation of many 
proteins important for the G1 to S phase transition of the cell cycle (Figure 3-8A). To 
confirm the critical nature of CARM1 in cell cycle control, the expression of a panel of 
cell cycle regulators was assessed (Figure 3-8B). We found that p21 mRNA (Figure 3-
5B) and protein levels (Figure 3-8B) were increased in the absence of CARM1, with p27 
similarly upregulated (Figure 3-8B). Downstream of these proteins, CDK-2 protein levels 
were undetectable in CARM1 null MEFs. In addition to the ability of p21 and p27 to 
inhibit its activity, this CARM1-dependent depletion of downstream factors may suggest 
redundancy in regulation. Also consistent with microarray results, we found that RB was 
slightly upregulated in the absence of CARM1 (Figure 3-8B). CDK-4 and CDK-6 levels 
were not significantly altered (not shown), and while the upstream cyclin dependent 
kinase inhibitors p15 and p16 were both shown by microarray to be significantly 
downregulated in the absence of CARM1, protein levels were minimal, and we were 
unable to confirm this change in expression. To determine if the extensive involvement of 
CARM1 in affecting the expression of cell cycle regulators had functional impact, we 
subjected wildtype and knockout MEFs to the additional stress of a cell replication 
inhibitor, hydroxyurea (HU), and assessed cellular proliferation. When treated with HU, 
the proliferation of CARM1+/+ MEFs arrests (Figure 8C). By comparison, the effect of 
HU on CARM1-/- MEFs was much more severe. Not only was proliferation inhibited in 
the knockout MEFs; cell number was notably diminished with increasing time post-
treatment (Figure 8B). The observations that in the absence of CARM1 the expression of 
many cell cycle regulators is dramatically altered, and that cells become sensitized to 
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additional stressors, suggests an important role for CARM1 in maintaining cellular 
growth and proliferation. 
 
3.3 Discussion 
In the present study we assessed the role of CARM1 in transcriptional regulation 
using a global genomic approach. The importance of CARM1 in transcriptional 
regulation is becoming increasingly appreciated, and several studies have assessed 
CARM1 activity on a genome-wide scale, as indicated by the presence of asymmetrically 
dimethylated histone H3R17  [23], or the presence of coregulators specifically 
methylated by CARM1  [24]. Furthermore, our previous work examined the recruitment 
of CARM1 as part of a p/CIP/CARM1 coregulatory complex to a subset of E2-dependent 
promoters in MCF-7 breast cancer cells  [25]. However, these studies have not 
considered CARM1 recruitment in the absence of an extrinsic stimulus or interacting 
partners mediating its recruitment.  
Herein we present the first direct assessment of genome-wide CARM1 
recruitment. Using ChIP-Seq, we identified 7022 genome-wide CARM1 binding events, 
and highlighted a subset of 432 statistically enriched, high confidence regions. In 
addition, microarray analysis of wildtype and CARM1-null MEFs revealed 643 
differentially expressed genes; 147 of these genes were shown to have a CARM1 binding 
event occur within 50 kb, and 58 differentially expressed genes have binding that occurs 
within 5kb (Table 3-2). Therefore, CARM1 recruitment does not appear to be predictive 
of gene expression, at least not in the absence of an extrinsic signal.   
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Figure 3-7 Characterizing some of the functional consequences of CARM1 loss 
(A) Pie chart representing enrichment of GO terms implicated among genes differentially 
expressed in CARM1-/- vs. CARM1+/+ MEFs. Analysis indicates a prevailing role for CARM1 in 
biological processes, specifically metabolic processes, and growth, and cellular processes. (B) 
The effects of CARM1 on cellular proliferation. The Moxi Z automated cell counter was used to 
assess cellular proliferation in wildtype and CARM1-null MEFs as well as  (C) cell diameter, and 
(D) cell volume.  
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Characterization of genomic CARM1 activity in MCF7 cells by Lupien et al. 
identified 4088 sites of H3R17 dimethylation in cells that were not treated with E2  [23]. 
Despite the difference in cell lines between their study and ours, the distribution of 
H3R17me2 bears striking similarity to the distribution of CARM1 binding events we 
observed. Corresponding to the observation that 55% of dimethylated H3R17 exists in 
intergenic regions, we noted that CARM1 also predominates intergenically (66-69%), 
where binding events occur some distance from transcriptional start sites. 
Another consistent feature of both studies is the prevalence of CARM1 binding 
events (19-20%), and H3R17me2 enrichment (~40%) within the coding sequence of 
genes  [23]. Due to the frequency of CARM1 binding within the coding sequence (CDS), 
coupled with previous evidence suggesting that the transcriptional elongation-associated 
Paf1c complex interacts with H3R17me2  [17], we assessed whether these two factors 
directly interact, and show by co-immunoprecipitation that Paf1c interacts with CARM1 
(Figure 3-1D). Wu et al. demonstrated that in the absence of CARM1 and a 
corresponding loss of H3R17me2 genome-wide, Paf1c occupancy at E2-dependent 
proximal promoters was decreased  [17]. We would suggest that this observed loss of 
occupancy might, at least in part, be a direct consequence of the absence of CARM1.  
Investigation of enriched transcription factor binding motifs within CARM1 
binding regions was performed to determine whether a previously unidentified protein 
facilitates CARM1 genomic interaction in an un-induced model. Interestingly, of the five 
most enriched TF motifs identified in our study, three of them have previously 
documented roles in transcriptional repression  [26-28]. We found that the most enriched 
transcription factor motif among CARM1-binding regions recognized PAX1, and that 
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PAX1 motifs correspond with the most statistically enriched, high-confidence binding 
regions for CARM1 in 45% of cases (Figure 3-3C). We evaluated and confirmed 
CARM1 recruitment at several regions containing PAX1 recognition sites, and 
subsequently demonstrated that CARM1 binding at these regions is diminished when 
PAX1 was depleted (Figure 3-4). In 2012, CARM1 was reported to interact with PAX7  
[29].  Deletion construct analysis conducted by that group revealed the CARM1-binding 
region to be found within the paired domain, and suggested that this ability to interact 
with CARM1 may be conserved among the paired box domain (Pax) family, all members 
of which share this domain  [30]. Collectively, this evidence suggests that Pax family 
members, may mediate a subset of genome-wide CARM1 recruitment, and herein we 
present supporting examples of PAX1-dependent CARM1 recruitment. PAX proteins 
function as transcription factors, and are important for many cellular processes during 
embryonic development  [31]. During development, PAX1 is expressed in the skeleton, 
thymus, as well as the 3rd and 4th pharyngeal pouch  [31]. Similar to the CARM1 
knockout mouse  [14], PAX1 null mice have a reduced thymus  [32]. In addition, the 
PAX1 knockout has abnormalities in development of the tail, vertebral column, sternum, 
and scapula  [33]. CARM1 has been shown to be important for endochondral bone 
formation  [34], and CARM1 null mice are much smaller than wildtype counterparts  
[14]. The similarities between PAX1 and CARM1 knockout mice suggest a potential 
overlap in developmental regulatory roles. It is likely that the role of PAX1 in recruiting 
CARM1 to the genome is relevant only during developmental stages, since its expression 
is generally limited to this stage  [30,35].  
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Figure 3-8 CARM1-dependent regulation of the cell cycle proteins. 
(A) Overview of proteins involved in the G1-S phase transition of cell cycle, adapted from Cell 
Signalling Technology. (B) Western Blot analysis analyzing the expression of cell cycle 
regulatory proteins (p21, p27, CDK-2, RB) in CARM1-/- and CARM1+/+ MEFs. Vinculin was 
used as a loading control, and representative images are shown from at least two independent 
replicates. (C & D) The Moxi Z automated cell counter was used to assess cellular proliferation in 
(C) wildtype and (D) CARM1-null MEFs following treatment with 0.1 mM hydroxyurea (HU). 
MEFs were seeded 24hrs prior to exposure to HU, and proliferation was assayed following 24 
and 48hrs of HU exposure. Data is expressed as a bar chart, depicting the mean and standard error 
of the mean from two independent experiments. 
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Functional analysis revealed cellular growth to be one of the primary biological 
processes affected by CARM1 loss (Figure 3-7A). Consistent with this result, we showed 
that CARM1-/- MEFs proliferate at a reduced rate when compared with CARM1+/+ MEFs 
(Figure 3-7B). Furthermore, the CARM1-null cells were smaller in diameter and had a 
reduced cell volume (Figure 3-7 C & D). These observations are consistent with our 
findings that a substantial number of genes involved in cell cycle control were 
differentially expressed in the absence of CARM1 based on microarray analysis (Figure 
3-8A). Cell growth in MCF-7 cells that are depleted of CARM1 has been shown to be 
reduced  [13]. These cells have a corresponding increase in E2F1, and recruitment of 
CARM1 to the E2F1 promoter is evident  [13]. Previous studies also reveal that CARM1 
is recruited to the promoter of the cell cycle regulator cyclin E1, which it positively 
regulates in response to E2  [36]. While cyclin E1 and E2F1 are relatively downstream 
proteins in the signalling cascade that controls G1-S phase transition in the cell cycle, we 
notably observed CARM1-dependent differential expression in several of the more 
upstream regulators (Figure 3-8A). The cyclin-dependent kinase inhibitors p21 and p27 
were both upregulated in the absence of CARM1, and CDK-2 expression is also 
diminished (Figure 3-8B). While our ChIP-Seq did not reveal CARM1 binding events in 
the promoters of p21 or p27, this does not exclude the possibility that these genes could 
be directly targeted by CARM1 in an induced system. Alternatively, these cell cycle 
regulators may be modulated by CARM1-dependent changes in TF and/or coregulator 
activity. For example, a mechanism for the regulation of p21 involving CARM1 has been 
previously characterized, wherein p53 and BRCA1 cooperate with p300 and CARM1 in 
response to DNA damage to induce expression of p21  [3]. Further demonstrating the 
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critical nature of CARM1-dependent changes in the expression of cell cycle proteins, the 
addition of a stressor in the form of hydroxyurea (HU) to the compromised cell cycle of 
the CARM1-/- MEFs resulted in substantial loss of cell viability (Figure 3-8D) as 
compared to the proliferative pausing seen in the uncompromised wildtype MEFs (Figure 
3-8C).  
 This study represents the first direct assessment of CARM1 recruitment on a 
genome-wide scale. We describe a pattern of CARM1 binding consistent with other 
transcriptional regulators, and suggestive of involvement in transcriptional elongation. 
Furthermore, we identify PAX1 as a novel interacting protein for CARM1 and a likely 
mechanism for CARM1 recruitment during development. Finally, while direct 
recruitment of CARM1 does not appear to be essential for the transcriptional change(s) 
observed, regulation of cellular growth and proliferation appear to be critically regulated 
by CARM1.  
 
3.4 Materials and Methods 
3.4.1 Cell Culture and Reagents 
The generation of CARM1-/- mice, and extraction of MEFs has been previously 
described  [14]. CARM1-/- and age-matched wildtype (CARM1+/+) MEFs were cultured 
in Dulbecco’s Modified Eagle Medium (Wisent), supplemented with 10% Fetal Bovine 
Serum (Wisent), and penicillin/streptomycin (Wisent), and maintained at 37°C and 5% 
CO2. All siRNA used in this study was purchased from Dharmacon, and transfection 
protocol was followed according to the manufacturer’s recommendations. Cellular 
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growth characteristics were assessed using the Moxi Z automated cell counter (ORFLO 
Technologies). Hydroxyurea (HU) was purchased from Sigma (catalogue No.127-07-1). 
For cell proliferation assays, 106 cells were seeded in 6-well plates, allowed to attach for 
24hrs and then trypsinized and counted every 24hrs over 4 days. HU was added 24hrs 
post-seeding, and trypsinizing-cell counting cycles were started 24hrs later. 
3.4.2 Protein Extraction and Western Blotting 
Cells were harvested in RIPA lysis buffer, consisting of 50mM Tris (pH 8.0), 150mM 
NaCl, 1% NP-40, 0.1% SDS, and protease inhibitor cocktail. Extracts were incubated on 
ice for 10 min and  cleared by centrifugation for 10 min at 15,000 rpm at 4°C. Protein 
concentrations were determined, normalized, and proteins separated by SDS-PAGE, 
transferred to PVDF membrane, and blocked overnight in PBS containing 0.1% Tween-
20 and 5% nonfat dried milk, or with TBS containing 0.1% Tween-20 and 5% BSA. 
Membranes were probed with specific primary antibodies for 2 hrs at room temperature, 
followed by incubation with horseradish peroxidase-conjugated secondary antibodies for 
1 hour. Signals were detected using ECL according to the manufacturer’s 
recommendations (Amersham). Affinity purified anti-p/CIP antibody was generated as 
previously described  [37,38]. All other antibodies used were commercially purchased: 
CARM1 (Bethyl A300-421A and Epicypher 13-0006), SMAD2/3 (Santa Cruz sc-6202), 
p21 (Santa Cruz sc-6246), p27 (Santa Cruz sc-528), CDK-2 (Santa Cruz sc-6248), PAF1c 
(Bethyl A300-173A). An antibody recognizing RB (Santa Cruz sc-7905) was generously 
provided for our use by Dr. Fred Dick (UWO). 
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3.4.3 RNA Isolation and real-time PCR 
Total cellular RNA was isolated using RNeasy kit (Qiagen) in accordance with 
the manufacturer’s directions. The quality and quantity of RNA was evaluated based on 
relative absorbance at OD 260/280. For quantitative real-time PCR analysis, 2µg of RNA 
was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems). Amplification was detected using predesigned and quality tested 
5’ nuclease Taqman probes (Applied Biosystems). Reactions were performed in 
accordance with manufacturer’s recommendations and technical duplicates were run in a 
96-well format using StepOne Plus Real-time PCR System (Applied Biosystems). Gene 
expression levels were determined based on the cycle threshold (Ct) and 18S ribosomal 
RNA was used for normalization. Reactions in the absence of cDNA served as negative 
controls.  
3.4.4 Expression Microarray 
Total RNA was extracted from CARM1+/+ and CARM1-/- MEFs, as described 
above. Duplicate experiments were performed. cDNA was prepared from each sample, 
labeled, and hybridized to Mouse Gene 1.0 ST arrays. Hybridization, washing, scanning, 
and analysis of gene chips were performed at the University of Western Ontario, London 
Regional Genomics Centre (London, Ontario, Canada). Probe level data was generated 
and summarized to gene level data in Partek Genomics Suite and adjusted for 
background. A 1-way ANOVA was performed contrasting expression in CARM1-/- and 
CARM1+/+ MEFs and a list of genes that showed a 2-fold or greater change in expression 
with an unadjusted p-value of 0.01 was generated.  
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3.4.5 Chromatin Immunoprecipitation and ChIP-Seq 
CARM1+/+ and CARM1-/- MEFs were cross-linked with 1% paraformaldehyde at 
room temperature for 10 min. Cross-linking was quenched by washing cells twice with 
ice cold PBS containing PMSF. Cell pellets were lysed in lysis buffer (50mM Tris-HCl 
[pH 8.1], 10mM EDTA, 1% SDS, and protease inhibitors) and incubated on ice for 10 
min. Lysates were sonicated to yield chromatin fragments approximately 300bp – 1000bp 
in length, and ChIP experiments were performed as previously described  [25,39], using 
antibodies against CARM1 and IgG (2-8µg). 
Immunoprecipitated DNA was purified using QIAquick PCR Purification Kit 
(Qiagen), and was analyzed either by conventional end-point PCR, or by quantitative 
PCR following ChIP (qChIP), as previously described  [25,39]. Quantitation was 
performed on a StepOne Plus Real-time PCR System (Applied Biosystems). The signal 
from IgG ChIP experiments was subtracted from the signal obtained using the specific 
antibody. 
The chromatin immunoprecipitation assay used prior to deep sequencing analysis 
was modified such that sonication conditions produced genomic fragments in the 250-
350 bp range. The isolated DNA was sequenced at the University of British Columbia 
(http://www.cmmt.ubc.ca/facilities/services/sequencing) using the Illumina sequencing 
platform. The obtained reads were then aligned to the mouse genome (MM9) in Partek 
Flow using Bowtie (version 0.12.7). Peaks were called using 125bp window in Partek 
Genomics Suite. Primers used for ChIP experiments are listed in Appendix C. 
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3.4.6 Transcription Factor Motif Enrichment Analysis 
Partek Genomics Suite was used to identify enriched TF binding motifs within 
CARM1 binding regions. Briefly, peak sequences were scored against motif models from 
the JASPAR database (http://jaspar.cgb.ki.se/). Motif instances within CARM1 peaks 
were called if their score exceeded 0.7 sequence quality. CARM1 bound sequences were 
also interrogated using Partek Genomics Suite to identify a de novo binding motif using 
the Gibbs motif sampling method [40]. A 14bp de novo binding motif was identified by 
this approach CARM1 peak sequences. 
3.4.7 Gene Ontology Analysis 
GO analysis was performed using Partek Genomics Suite. Enriched functional 
groups were identified using Fischer’s Exact. Functional groups were reported if 2 or 
more genes were represented. Gene Ontology default background file (Mus musculus-
2012-11-19-MoGene-1_0-st-v1) was used for gene background correction. 
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  Chapter 4
 General Discussion 4
4.1 Thesis Summary 
 The focus of this thesis is the role of CARM1 in global gene regulation. CARM1 
is known to methylate a wide array of proteins important for transcription, including 
transcription factors, coregulators, and components of the core transcriptional machinery  
[1-3]. However, its characterization to date has been limited by an emphasis on its ability 
to interact with and regulate the function of specific transcriptional regulators on a gene-
by-gene basis and in response to extrinsic signals  [4-6]. In Chapter 2, I extend the current 
understanding of CARM1 in one of its more well-defined roles, as a secondary 
coregulator in E2-dependent gene expression. Using a global genomic approach, I have 
characterized its participation as part of a coregulatory E2-dependent p/CIP/CARM1 
complex, identifying a subset of gene promoters to which this complex is recruited in 
response to E2  [7]. I focus on the recruitment of a functional p/CIP/CARM1 complex to 
the proximal promoter of Jak2, and demonstrate that complex recruitment leads to 
transcriptionally permissive changes in histone modifications.  
In Chapter 3 I identify the genomic sites with which CARM1 interacts in a 
specific cell system irrespective of binding partner(s) and in the absence of induction. 
This characterization of global CARM1-binding events suggests a role for CARM1 in 
transcriptional elongation. Additionally, I have identified the PAX1 transcription factor 
as a potential binding partner for CARM1 based on the inability of CARM1 to bind 
regions containing PAX1 consensus motifs following siRNA-mediated depletion of 
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PAX1. Functional analysis of CARM1-dependent genes implicates a critical role for 
CARM1 in cellular growth and proliferation. CARM1 has previously been shown to 
affect cell growth  [8], and affect specific cell cycle regulators  [8-10]. I demonstrate that 
hydroxyurea treatment of wildtype MEFs, in which cell cycle proteins are expressed 
normally, results in proliferative pausing. By comparison, in CARM1 null MEFs there 
are widespread changes in the expression of cell cycle regulators and hydroxyurea 
treatment results in loss of viability, suggesting a role for CARM1 in sensitizing cells to 
cell cycle stress. 
 
4.2 p/CIP/CARM1 Complex Recruitment 
p/CIP is a well validated nuclear receptor coactivator that has been shown to 
associate with numerous ER-dependent promoters including the pS2 (also known as 
TFF1)  in response to E2 treatment in MCF-7 cells  [11]. p/CIP is known to act as a 
scaffold protein, and facilitate the assembly of coregulatory complexes  [11,12]. In 
addition, p/CIP and CARM1 have been shown to synergistically coactivate transcription  
[13]; and subsequent studies showed by sequential ChIP analysis that a p/CIP/CARM1 
complex is recruited to pS2, facilitating its transcriptional activation  [4,5].  
Using a ChIP-DSL approach, 204 additional proximal promoters to which the 
p/CIP/CARM1 complex binds in response to E2 were identified (Table B-1). Although 
ChIP-DSL technology is now outdated, the assay is highly sensitive, and eliminates many 
of the biases of the ChIP-on-chip whole-genome tiling arrays more commonly used at the 
time. ChIP-DSL was described in 2007  [14]. This technique uses immunoprecipitated 
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DNA only as a template to mediate annealing and ligation of aligned oligonucleotide 
pairs, instead of directly amplified DNA for hybridization. Adjacent oligonucleotide pairs 
ligate to form complete amplicons, which corresponding to regions from unique gene 
promoters. The use of unique promoter sequences eliminates potential interference from 
repetitive or related sequences during amplification. The primary limitation of this 
approach is that analysis is restricted to the 1 kb of upstream regulatory promoter 
sequence of genes found on the array. However, a major advantage of the approach is 
that targeted sequences are directly associated with known genes, thereby eliminating the 
complicated process of assigning responsive genes to distant binding sites.  
In 2010, global E2-dependent binding sites for p/CIP were identified  [15]. This 
study suggested that only a minority (~3%) of E2-dependent p/CIP binding occurs within 
500 bp of the TSS, a finding that is consistent with accumulating genomic analysis 
indicating that ER primarily interacts with regions some distance (>10kb) from the TSS  
[16,17]. In addition, the level of CARM1 activity (as assayed by its methylation of 
H3R17 and/or indirectly p/CIP binding [based on recognition of arginine-methylated 
p/CIP], across the genome also appears to cluster predominantly upstream of the 1kb 
promoter region  [18]. Despite the fact that genomic binding of these factors is becoming 
increasingly understood to be more prevalent outside of the promoter context, promoter 
proximal interactions do occur in response to E2 and these binding events can have 
transcriptional consequences. Our discovery of 204 E2-dependent target promoters for 
the p/CIP/CARM1 complex corresponds with the observations of a limited set of 
proximal promoter binding sites for p/CIP, and with the evidence of minimal CARM1 
methylation activity at promoter elements.  
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Both p/CIP and CARM1 have been implicated in aggressive breast cancer  [19-
21], with demonstrated roles in E2-induced proliferation of the MCF-7 breast cancer cell 
line  [22-24]. Ingenuity Pathway Analysis conducted on the identified p/CIP/CARM1 
targets implicated a notable proportion of these genes as having an involvement in 
cancer, with several cancer initiation- and progression-related molecular and cellular 
processes ranking highly (Figure 2-5). Collectively, these data suggests that while 
promoter-proximal recruitment of E2-dependent transcriptional regulators is rare, 
recruitment of the p/CIP/CARM1 complex to a subset of promoters is likely functionally 
relevant.  
 
4.3 Transcriptional effect of the E2-dependent 
p/CIP/CARM1 complex recruitment 
Past studies featuring microarray analysis following E2-stimulation of MCF-7 
cells can be broadly categorized based on the length of hormone treatment. There is an 
observable difference in the pattern of expression change, such that at early time points 
(<6 h) more genes are upregulated and more variation is evident between time points, 
while at later time points (>12 h) there is a more stable pattern of expression change and 
the majority of genes are downregulated  [16,25]. We examined changes in mRNA 
expression following 12 h of stimulation with E2, and showed that approximately 20% of 
p/CIP/CARM1 complex target genes identified by ChIP-DSL were transcriptionally 
altered (16.2% upregulated and 3.9% downregulated). The relatively small number of 
differentially expressed target genes after 12 h suggests that proximal recruitment of the 
p/CIP/CARM1 complex is not predictive of E2-dependent gene expression at this late 
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time point. However, that does not necessarily mean that the p/CIP/CARM1 complex is 
not active in regulating transcription. Transcription of protein coding genes is primarily 
performed by RNAPII  [26]. As an alternate method of determining immediate 
transcriptional response assessment of RNAPII recruitment to proximal promoters in 
response to extrinsic signal, and corresponding to coregulator or transcription factor 
recruitment, is suggestive of active gene expression  [16,17]. When the list of 
p/CIP/CARM1 complex targets is compared with RNAPII-bound promoters  [16], 86/204 
(42%) genes were bound by both p/CIP/CARM1 and RNAPII in response to E2. This 
observation supports the suggestion that proximal promoter recruitment may be more 
relevant for more immediate transcriptional response. A recently developed technique, 
‘Global Run-On Sequencing’ (GRO-seq), would allow for further confirmation that 
p/CIP/CARM1 plays a role in rapidly inducing gene expression. This assay maps the 
position, amount, and orientation of transcriptionally engaged RNA polymerases 
genome-wide  [27]. GRO-seq analysis following E2 treatment was recently published and 
showed that E2-signaling regulates a large proportion of the transcriptome, and 
demonstrated that intergenic ER binding is transcriptionally relevant  [28]. Unexpectedly, 
the observed transcriptional effects were revealed to be quite transient, suggesting that 
longer E2 treatment times previously utilized to allow for mature mRNA accumulation 
likely have not provided a comprehensive understanding of E2-dependent transcriptional 
regulation.  
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4.4 CARM1 is the functional component of p/CIP/CARM1 
complex 
Several studies have demonstrated a correlation between recruitment of CARM1, 
methylation of histone H3, and activation of several steroid responsive genes  [29-31]. 
The methyltransferase activity of CARM1 is critical for this ability to enhance 
transcriptional activation by NRs and p160 coactivators  [32]. Interestingly, methylation 
of H3R17 and/or p/CIP has been detected at 70% of the ER cistrome in MCF-7 cells, and 
CARM1 activity genome-wide was found to be predictive of ‘active’ ER sites  [18].  
Importantly, we noted a statistically significant E2-dependent enrichment in 
H3R17me2 on the Jak2 promoter, corresponding with p/CIP/CARM1 recruitment, 
suggesting the complex [and specifically CARM1] is functional (Figure 2-6). Reinforcing 
this suggestion, we observed a decrease in E2-dependent H3R17me2 of the Jak2 
promoter following depletion of p/CIP, as well as a reduction in E2-induced transcription 
of Jak2 (Figure 2-7). Depletion of CARM1 caused a more dramatic loss in E2-dependent 
Jak2 transcription, suggesting that its enzymatic activity is in fact important for the 
regulation of Jak2 by the p/CIP/CARM1 complex. JAK2 is a central component of the 
Jak/Stat signalling pathway and is responsible for phosphorylation and activation of the 
STAT family of proteins, which normally reside in the cytoplasm and, upon activation, 
translocate to the nucleus and bind to specific target genes involved in cell proliferation 
and survival  [33]. JAK2 null mice display phenotypes similar to the ERα and p/CIP 
knockout animals including defects in mammary gland cell proliferation and apoptosis  
[34,35]. Furthermore, E2 is known to stimulate phosphorylation and activation of STAT3 
and 5, although the mechanism has not been fully elucidated  [36-38]. We demonstrate a 
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reduction of E2-indced STAT3 phospohorylation following siRNA-mediated depletion of 
p/CIP and/or CARM1 (Figure 2-7), suggesting that targeting of JAK2 by the 
p/CIP/CARM1 complex may contribute to E2-dependent modulation of this signalling 
pathway. 
 
4.5 Characterizing genome-wide CARM1 binding  
 In Chapter 3 I describe our analysis of global CARM1 recruitment in MEFs. The 
use of CARM1 wildtype and knockout MEFs provides a physiologically normal cell 
system in which the relevance of direct CARM1-dependent gene regulation can be 
studied. Conducting such an examination in the absence of any extrinsic signal is novel 
and allows for a broader understanding of CARM1 action, without limiting its 
functionality to specialized cellular programs or particular disease states. This study 
represents the first time that CARM1 binding has been directly considered on a genome-
wide scale. Using ChIP-Seq, 7022 CARM1-dependent peaks were identified, and using 
statistical filtering methods 432 high-confidence binding regions were delineated. 
Analysis of the distribution of binding events revealed a predominance of binding events 
occurring at regions distal from the TSS of genes (Figure 3-1). Approximately 6% of 
CARM1 peaks correspond to promoter regions (defined as 5kb upstream and 1kb 
downstream of TSS), representing 421/7022 peaks. The observation that only a small 
proportion of recruitment occurs within the proximal promoter has become a consistent 
feature of the genome-wide characterization of transcriptional regulators. The existence 
of primarily distal binding sites raises the question of how such binding events can 
influence transcription. Technologies have evolved to address these questions, and the 
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use of ‘chromosome conformation capture’ (3C) and/or ‘chromatin-interaction analysis 
by paired end tag sequencing’ (ChIA-PET) have established a paradigm of chromosomal 
looping that brings distal ER binding sites into contact with TSS  [39,40]. Importantly, 
RNAPII occupancy is enriched at genes where looping occurs  [40], suggesting that this 
mechanism of bringing distal regulatory elements into contact with the TSS is 
functionally relevant for transcriptional control. Hah et al. later demonstrated that, in 
addition to this looping, a class of primary transcripts (eRNA) is expressed from ER-
associated distal enhancer regions  [41]. Future work to assess whether looping events 
bring CARM1 into contact with TSS would supplement our understanding of its role in 
regulating transcriptional initiation. An additional avenue to be pursued, which will more 
fully clarify CARM1’s transcriptional relevance, will be to characterize the global 
deposition of the CARM1-dependent histone modification, H3R17me2, by ChIP-Seq. 
The presence of H3R17me2 is reflective of CARM1 activity, and will provide insight 
into the mechanism of CARM1 action at different genomic locations. 
 We have previously demonstrated that E2-dependent interaction of CARM1 with 
the genome can be mediated through p/CIP [and the ER]  [7]. Additionally, CARM1 is 
known to be recruited in a complex with transcription factors such as E2F1  [8], β-catenin  
[42], and NF-kB  [43]. In an attempt to identify other transcription factors that may 
facilitate CARM1 binding, we used a bioinformatic approach and assessed the 
enrichment of TF binding motifs present within identified CARM1 peaks. The five most 
enriched TF motifs were found to correspond with Hunchback (PAX1), ZNF354C, YY1, 
Gfi, and MZF1 (Figure 3-3A). Notably, YY1 has been shown to recruit PRMT1, a 
CARM family member, to activated promoters  [44]. This does not necessarily suggest 
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that a CARM1-YY1 interaction exists. However, since the central (methyltransferase 
region) of CARM1 shares a high degree of homology with PRMT1  [13,32], it seems 
possible that a similar, albeit context-dependent, association with YY1 may occur. Our 
experimental focus, however, was on the most enriched motif, PAX1. De novo motif 
discovery produced a strikingly similar motif to the PAX1 consensus site (Figure 3-3B). 
Next, we validated using quantitative ChIP analysis that CARM1 was binding at regions 
containing PAX1 motifs (Figure 3-4A). Ultimately, the strongest evidence suggesting 
that PAX1 may facilitate CARM1 genomic recruitment came from the observation that 
when PAX1 was depleted using siRNA, there was a reduction in CARM1 enrichment at 
analyzed regions (Figure 3-4B). While this is the first evidence that PAX1 may facilitate 
genomic recruitment of CARM1, it is not the first time CARM1 has been shown to 
interact with the paired box (Pax) protein family. CARM1 has been shown to interact 
with PAX7  [45], with the CARM1-binding region present within the paired domain. 
Taken together, these findings suggest that the ability to interact with CARM1 may be 
conserved among the paired box domain (Pax) family. It is likely that the role of PAX 
proteins in recruiting CARM1 to the genome is relevant only during developmental 
stages, since their expression is generally limited to this stage  [46,47]. 
 
4.6 CARM1 in Transcriptional Elongation 
Arginine methylation of transcriptional elongation factors by PRMT family 
members has been previously demonstrated, with PRMT1 and PRMT5 affecting 
association between SPT5 and RNAPII, resulting in transcriptional pausing  [48]. In 
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addition, PRMT7 can symmetrically dimethylate eukaryotic elongation factor 2 (eEF2)  
[49]. The evidence linking CARM1 with transcriptional elongation has been more 
indirect. Several components of the transcriptional elongation-associated Paf1c complex 
have been shown to interact with the CARM1-specific histone modification H3R17me2  
[50]. CARM1 can also methylate the C-terminal domain of RNAPII, and contribute to 
transcriptional activation by creating docking sites for effector protein(s)  [3]. 
Our assessment of the genomic distribution of CARM1 peaks revealed that 20% 
(1404/7022) of binding events occurred within gene bodies (Figure 3-1). These binding 
events could reflect a role for CARM1 in alternative splicing and mRNA processing, a 
function in which CARM1 has already been implicated through its methylation of several 
splicing factors  [51]. Alternately, the predominance of binding sites within the CDS of 
genes could also be indicative of a direct role for CARM1 in transcriptional elongation. 
To address this possibility, we performed co-immunoprecipitation experiments in 
CARM1+/+ MEFs and demonstrated an interaction between CARM1 and Paf1c (Figure 3-
1D). Furthermore, we attempted to discern an association between CARM1 and activated 
RNAPII, however these experiments are currently ongoing. Taken together, the 
predominance of CDS binding sites and the demonstration that CARM1 directly interacts 
with the elongation-associated Paf1 compex presented within this thesis provides 
evidence to support the involvement of CARM1 in transcriptional elongation. Future 
work will need to be conducted to fully elucidate its regulatory role in this stage of gene 
expression. 
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4.7 Functional Impact of CARM1 
 Functional analysis of the genes targeted by the p/CIP/CARM1 coregulatory 
complex implicated cancer as one of the primary diseases affected by their misregulation. 
Furthermore, processes including cellular growth and proliferation, development, cell-to-
cell signaling, and morphology were associated with this gene set (Figure 2-5). It is 
interesting to note that when functional analysis is conducted on genes differentially 
expressed in the absence of CARM1, similar cellular processes were implicated (Figure 
3-7). Since sustained proliferation is one of the most fundamental characteristics of 
cancer cells  [52], and functional analysis implicated growth characteristics as being 
critically regulated by both CARM1- and p/CIP/CARM1-regulated genes, we further 
analyzed the impact of CARM1 in this process. 
CARM1 has been previously implicated in growth as well as cell cycle control. 
CARM1 knockout mice are small in size, and NF-kB dependent gene expression, 
important for cellular events such as apoptosis, cell proliferation, and differentiation, is 
impaired in CARM1-null MEFs  [53]. CARM1 also plays a role in ERα-­‐‑dependent breast 
cancer cell differentiation and proliferation  [24,54]. In response to DNA damage 
CARM1 methylates the p300 KIX domain, promoting recruitment of BRCA1 by p300 to 
the p53-responsive promoter of p21 and inducing increased p21 expression  [10]. 
CARM1 is also recruited to the promoter of cyclin E1 (CCNE1) in an E2F-dependent 
manner, and functions as a positive regulator of transcription  [8]. Our analysis of growth 
characteristics revealed that CARM1 null MEFs proliferated at a reduced rate when 
compared to wildtype (Figure 3-7B) and had a smaller cell diameter and cell volume 
(Figure 3-7D). Furthermore the expression of a large number of proteins known to 
140 
 
regulate cell cycle was altered in the absence of CARM1 (Figure 3-8). To determine if 
involvement of CARM1 in regulating the expression of cell cycle regulators has 
functional impact, we subjected wildtype and knockout MEFs to the additional stress of a 
cell replication inhibitor, hydroxyurea (HU), and found a substantial loss of cell viability 
when CARM1 was absent. The suggestion that loss of CARM1 may sensitize cells to 
replicative stress needs to be further evaluated in the future, and the model tested in 
cancer cell lines known to have elevated CARM1. Alternately, and arguably of more 
translational relevance, CARM1 expression could be assessed, along with the expression 
of some of its downstream targets (ex. JAK2, p21) in breast tumor samples. Stratifying 
tumors based on the presence or absence of CARM1 may allow for diagnostic and/or 
prognostic inferences to be made with respect to the delineation of breast cancer 
subtypes, and could ultimately suggest different therapeutic strategies. For example, 
reduction of CARM1, or of its methyltransferase activity through the use of CARM1 
inhibitors  [55,56], may prove to be a successful treatment approach when used in 
combination with cell cycle inhibitors for cancers expressing high levels of CARM1.  
 
4.8 Conclusions 
 The use of whole-genome approaches to characterize the role of the arginine 
methyltransferase CARM1 in transcriptional regulation has advanced our understanding 
of the myriad roles it plays. The work presented within this thesis describes the 
recruitment of a functional p/CIP/CARM1 coregulatory complex to gene promoters in an 
E2-dependent manner. Bioinformatic analysis suggests that direct binding via a classical 
ERE is not the primary mechanism by which the complex is recruited, reinforcing 
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accumulating evidence that transcription factor crosstalk commonly occurs in ER-
mediated transcription. I focus on the recruitment of a functional p/CIP/CARM1 complex 
to the proximal promoter of Jak2, and demonstrate that regulation of Jak2 expression is 
contingent on the presence of CARM1.  
 CARM1 recruitment was also characterized independent of p/CIP, and found to 
bind predominantly at intergenic regions, consistent with the profiles of many other 
transcriptional regulatory proteins. Enrichment of CARM1 binding events was also found 
within the coding sequence of genes, suggesting an involvement in transcriptional 
elongation; in support of this, interaction between CARM1 and the elongation-associated 
Paf1c was confirmed. In addition, we identified the transcription factor PAX1 as a novel 
mechanism through which CARM1 can interact with the genome. Overall, this study 
suggested that direct genomic recruitment of CARM1 is not critical for its transcriptional 
and functional effect(s) in an un-induced system; however, we observed an important 
regulatory role for CARM1 in cellular growth and proliferation.  
Moving forward, there are many more avenues to be pursued before we gain a 
complete understanding of the many ways in which CARM1 contributes to the regulation 
of gene expression, and affects diverse cellular processes. As technology advances, we 
will be able to more fully characterize the coordinated action of transcriptional regulators 
such as CARM1.  
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Figure B-1 Co-occurrence of TF binding motifs in p/CIP/CARM1 target promoters 
(A) Chart showing the overlap between ERE, Sp1, AP-1, FoxA1, C/EBPα, and Oct consensus 
sites. The left column indicates the query motif(s), and the percentage of those promoters 
containing overlapping motifs is listed left to right. Cells are color coded according to the 
proportion overlap: red: >25% overlap, orange: 14-24.9% overlap, yellow <13.9% overlap. (B) 
Venn diagrams showing overlap between p/CIP/CARM1 target promoters containing EREs and 
those containing C/EBPα, Sp1, Oct, AP-1, or FoxA1 consensus sites. 
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FoxA1 (21)! 14.29%! 23.81%! 9.52%! 28.57%! 19.05%!
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Figure B-2 Additional binding site analysis of p/CIP/CARM1 target promoter 
sequences 
Bar graphs showing the number of (A) ER-bound and (B) transcriptionally upregulated 
p/CIP/CARM1 target promoters that contain ERE, Sp1, AP-1, FoxA1, C/EBP, and Oct binding 
motifs. 
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Table B-1 Genes directly targeted by the p/CIP/CARM1 complex. 
Gene ID Accession Number Description 
TLR3 NM_003265 Transmembrane receptor 
DBC1 NM_014618 Peptidase 
LAP3 NM_015907 Peptidase 
CLDN12 NM_012129 Calcium-independent cell-cell adhesion 
CRHR1 NM_004382 G-protein coupled receptor 
P181_E7 XM_372688 Transporter 
KRAS2 NM_033360 GTPase enzyme 
M6PR NM_002355 Mannose-6-phosphate receptor (cation dependent) 
PDCD8 NM_004208 Enzyme/cell death 
CIRBP NM_001280 Cold inducible RNA binding protein 
DLGAP3 XM_035601 Discs, large (Drosophila) homolog-associated protein 3 
AES NM_198969 Amino-terminal enhancer of split/transcriptional regualtor 
BTN2A2 NM_006995 Butyrophilin, subfamily 2, member A2 
C10orf111 NM_153244 Unknown 
STARD6 NM_139171 StAR-related lipid transfer (START) domain containing 6 
GNG5 NM_005274 Guanine nucleotide binding protein (G protein), gamma 5 
UNC13A XM_038604 Unc-13 homolog A (C. elegans) 
SLC4A5 NM_021196 Solute carrier family 4, sodium bicarbonate cotransporter, member 5 
PTER NM_030664 Phosphotriesterase related 
TRAF3 NM_003300 TNF receptor-associated factor 3/apoptosis 
C14orf29 NM_181533 Peptidase 
ZNF800 NM_176814 Unkown 
ARMC3 NM_173081 Armadillo repeat containing 3 
LETM1 NM_012318 Leucine zipper-EF-hand containing transmembrane protein 1 
IL15RA NM_002189 Interleukin 15 receptor, alpha 
MAPK4 NM_002747 Mitogen-activated protein kinase 4 
GTF2E2 NM_002095 General transcription factor IIE, polypeptide 2, beta 34kDa 
SEC31L1 NM_016211 SEC31 homolog A (S. cerevisiae)/vesicle transport 
KRTHA4 NM_021013 Keratin 34 
IGSF4/CADM1 NM_014333 Cell adhesion molecule 1/tumour suppressor 
CASP6 NM_001226 Caspase 6, apoptosis-related cysteine peptidase 
KIAA1340 XM_044836 KLHDC5 kelch domain containing 5 
DRF1 NM_025104 DBF4 homolog B (S. cerevisiae)/cell cycle regulator 
OCA2 NM_000275 Oculocutaneous albinism II 
LOC343066 XM_291392 Arylacetamide deacetylase-like 4 
SLC26A1 NM_022042 Solute carrier family 26 (sulfate transporter), member 1 
FRMD1 NM_024919 FERM domain containing 1 
AIP1 NM_012301 MAGI2 membrane associated guanylate kinase 
APRG1 NM_178338 Unknown/tumour suppressor 
CBR3 NM_001236 Carbonyl reductase 3 
FCGRT NM_004107 Fc fragment of IgG, receptor, transporter, alpha 
N4BP1 NM_153029 NEDD4 binding protein 1 
WDFY2 NM_052950 WD repeat and FYVE domain containing 2 
ZNF567 NM_152603 Transcription factor 
RAP140 NM_015224 Chromosome 3 open reading frame 63 
PELO NM_015946 Pelota homolog (Drosophila) 
OR51B4 NM_033179 Olfactory receptor, family 51, subfamily B, member 4 
SERPINB2 NM_002575 Serpin peptidase inhibitor, clade B (ovalbumin), member 2 
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DKFZP564I122 XM_032397 Methylmalonic aciduria protein 
SEC31L1 NM_014933 SEC31 homolog A (S. cerevisiae) 
TM4SF8 NM_005724 Tetraspanin 3 
NJMU-R1 NM_022344 Open reading frame 75 
CTNND1 NM_001331 Catenin (cadherin-associated protein), delta 1 
CDH7 NM_033646 Cadherin 7, type 2 
FLJ14054 NM_024563 Open reading frame 23 
OR5T3 XM_372393 Olfactory receptor, family 5, subfamily T, member 3 
TPARL NM_018475 Transmembrane protein 165 
CR2 NM_001877 Complement component (3d/Epstein Barr virus) receptor 2 
ZIM3 NM_052882 Zinc finger, imprinted 3/transcription factor 
VPS26A NM_004896 Vacuolar protein sorting 26  
MOCOS NM_017947 Enzyme 
POLR3F NM_006466 Enzyme 
MBD3 NM_003926 Methyl-CpG binding domain protein 3 
FLJ25467 NM_144719 Coiled-coil domain containing 13 
A2LP NM_007245 Homo sapiens ataxin 2-like (ATXN2L), transcript variant A 
OR6C1 XM_372459 Homo sapiens olfactory receptor, family 6, subfamily C, member 1 
RAD9B NM_152442 RAD9 homolog B (S. cerevisiae)/DNA replication 
ECT2 NM_018098 Epithelial cell transforming sequence 2 oncogene 
PCSK5 NM_006200 Proprotein convertase subtilisin/kexin type 5 
GATM NM_001482 Glycine amidinotransferase (L-arginine:glycine amidinotransferase) 
TUBGCP6 NM_020461 Tubulin, gamma complex associated protein 6 
KCTD16 XM_098368 Potassium channel tetramerisation domain containing 16 
CHRNA6 NM_004198 Cholinergic receptor, nicotinic, alpha 6 
TGFB1 NM_000660 Growth factor 
NEK4 NM_003157 Enzyme 
CPT1C NM_152359 Carnitine palmitoyltransferase 1C 
OR7A10 XM_372712 Olfactory receptor, family 7, subfamily A, member 10 
FLJ23584 NM_024588 Hypothetical protein 
RPS4X NM_001007 Ribosomal protein S4, X-linked 
FLJ34969 NM_152678 FAM116A family with sequence similarity 116, member A 
MGC11386 NM_032933 C18orf45 
ELAC1 NM_018696 ElaC homolog 1 (E. coli)/trna processing 
STARD4 NM_139164 StAR-related lipid transfer (START) domain containing 4 
HRASLS NM_020386 HRAS-like suppressor 
P188_B6 XM_374513 Similar to KIAA1218 protein  
ENO2 NM_001975 Enolase 2 (gamma, neuronal) 
P176_D4 XM_371127 Homo sapiens similar to putative protein 
PKP4 NM_003628 Plakophilin 4/cell adhesion 
KIF24 NM_018278 Homo sapiens kinesin family member 24 (KIF24) 
OR2AP1 XM_062467 Olfactory receptor, family 2, subfamily AP, member 1 
P155_A2 XM_036408 Unknown orf (KIAA1228) 
IFI6 NM_022873 Interferon, alpha-inducible protein 6/apoptosis 
DPH2L2 NM_001384 DPH2 homolog (S. cerevisiae) 
FUT7 NM_004479 Fucosyltransferase 7 (alpha (1,3) fucosyltransferase) 
SMARCAL1 NM_014140 SWI/SNF related, matrix associated, regulator of chromatin, a-like1 
CD9 NM_001769 CD9 molecule/cell adhesion 
LOC133609 XM_068430 Homo sapiens similar to 60S acidic ribosomal protein P1 
SRISNF2L NM_015106 RAD54-like 2 (S. cerevisiae) 
POLR2E NM_002695 Polymerase (RNA) II (DNA directed) polypeptide E, 25kDa 
NFKB1 NM_003998 Nuclear factor of kappa light polypeptide gene enhancer 
C9orf95 NM_017881 Orf 
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GNL1 NM_005275 Guanine nucleotide binding protein-like 1 
KRT20 NM_019010 Keratin 20/apoptosis 
TMEM16F XM_113743 Transmembrane protein 16F 
MGC15882 NM_032884 C1orf94 
IVNS1ABP NM_006469 Influenza virus NS1A binding protein 
DDX54 NM_024072 DEAD (Asp-Glu-Ala-Asp) box polypeptide 54/tranascriptional regulator 
WBP11 NM_016312 WW domain binding protein 11 
OR10A5 NM_178168 OR10A5 olfactory receptor, family 10, subfamily A, member 5 
SGK2 NM_170693 Serum/glucocorticoid regulated kinase 2 
BMI1 NM_005180 BMI1 polycomb ring finger oncogene 
LOC284275 XM_211413 Hypothetical protein 
K5B NM_173352 Keratin 5b 
MT1E NM_175617 Metallothionein 1E 
MT4 NM_032935 Metallothionein 4 
OTUB2 NM_023112 OTU domain, ubiquitin aldehyde binding 2 
THEG NM_199202 Theg homolog (mouse) 
CARD9 NM_022352 P111_E11 
ARHGAP8 NM_181335 Rho GTPase activating protein 8  
ITPKB NM_002221 Inositol 1,4,5-trisphosphate 3-kinase B 
LOC389253 XM_374104 Hypothetical protein 
C18orf26 NM_173629 Orf 
POLR2F NM_021974 Polymerase (RNA) II (DNA directed) polypeptide F 
LAMA1 NM_005559 Laminin, alpha 1/cell adhesion protein 
P139_A6 NM_152567 Arabidopsis thaliana chromosome 1 
SOD1 NM_000454 Superoxide dismutase 1, soluble 
P163_B12 XM_114325 Homo sapiens ubiquitin specific protease 19 (USP19) 
TSSC4 NM_005706 Tumor suppressing subtransferable candidate 4 
P181_D9 XM_372649 Hypothetical protein CBG22662  
MAP3K7IP1 NM_006116 Mitogen-activated protein kinase kinase kinase 7 interacting protein  
P2RY1 NM_002563 Purinergic receptor P2Y, G-protein coupled, 1 
FLJ46299 XM_093813 Homo sapiens similar to hypothetical protein (LOC166348) 
TSHB NM_000549 Thyroid stimulating hormone, beta 
RDH10 NM_172037 Retinol dehydrogenase 10 (all-trans) 
KCNQ1 NM_000218 Potassium voltage-gated channel, KQT-like subfamily, member 1 
RPS15 NM_001018 Ribosomal protein S15/translation 
LOC92691 NM_138390 Unknown 
KCTD3 NM_016121 Potassium channel tetramerisation domain containing 3 
HBD NM_000519 Hemoglobin, beta /// hemoglobin, delta 
LOC387635 XM_370532 Similar to ubiquitin-conjugating enzyme E2 variant 1 
PRKRIR NM_004705 Protein-kinase, interferon-inducible  RNA dependent inhibitor,  
RAB6IP1 XM_290550 RAB6 interacting protein 1 
RFXAP NM_000538 Regulatory factor X-associated protein 
HDC NM_002112 Histidine decarboxylase 
ZNF197 NM_006991 Zinc finger protein 197/transcription factor 
PCP4 NM_006198 Purkinje cell protein 4 
LRFN4 NM_024036 Leucine rich repeat and fibronectin type III domain containing 4 
ABAT NM_000663 4-aminobutyrate aminotransferase 
P186_C2 XM_373988 Homo sapiens similar to protein 40kD (LOC388290), mRNA. 
COL17A1 NM_000494 Collagen, type XVII, alpha 1 
PTPRJ NM_002843 Protein tyrosine phosphatase, receptor type, J 
PXMP4 NM_007238 Peroxisomal membrane protein 4, 24kDa 
JAK2 NM_004972 Janus kinase 2 (a protein tyrosine kinase) 
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PRSS15 NM_004793 lon peptidase 1, serine protease 
C6orf146 NM_173563 Orf 
LOC389439 XM_374187 Homo sapiens LOC389439 (LOC389439), mRNA 
TRO NM_177557 Trophinin/cell adhesion 
GPR132 NM_013345 G protein-coupled receptor 132 
HARS NM_002109 Histidyl-tRNA synthetase 
MDS009 NM_020234 DTWD1 DTW domain containing 1 
VN1R5 NM_173858 Vomeronasal 1 receptor 5 
CCNA2 NM_001237 Cyclin A2/cell cycle 
DMP1 NM_004407 Dentin matrix acidic phosphoprotein 
PCDHGC5 NM_018929 Protocadherin gamma subfamily C, 5 
POLG NM_002693 Polymerase (DNA directed), gamma 
ZBED2 NM_024508 Zinc finger, BED-type containing 2 
HSD17B12 NM_016142 Hydroxysteroid (17-beta) dehydrogenase 12 
LOC126298 XM_065026 Homo sapiens immunity-related GTPase family, Q (IRGQ), mRNA 
CSNK1A1L NM_145203 Casein kinase 1, alpha 1-like 
CYC1 NM_001916 Cytochrome c-1 
AKAP13 NM_006738 A kinase (PRKA) anchor protein 13 
LMOD1 NM_012134 Leiomodin 1 (smooth muscle) 
RBM29 NM_032213 RNA binding motif and ELMO/CED-12 domain 1 
P097_A6 NM_017597 Homo sapiens hypothetical protein 
LOC338731 XM_294688 Hypthetical protein 
LOC131873 XM_067585 Hypothetical protein 
MAP6 XM_166256 Microtubule-associated protein 6 
SS18L1 NM_015558 Synovial sarcoma translocation gene on chromosome 18-like 1 
PIAS2 NM_004671 Protein inhibitor of activated STAT, 2 
DPYS NM_001385 Dihydropyrimidinase 
RPS27L NM_015920 Ribosomal protein S27-like 
FXR1 NM_005087 Fragile X mental retardation, autosomal homolog 1 
NAGA NM_000262 N-acetylgalactosaminidase, alpha- 
IDH3G NM_004135 Isocitrate dehydrogenase 3 (NAD+) gamma 
PROS1 NM_000313 Protein S (alpha) 
DYRK1A NM_101395 Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A 
EDC3 NM_025083 Homo sapiens enhancer of mRNA decapping 3 homolog (S. cerevisiae)  
TNFRSF19L NM_152222 RELT tumor necrosis factor receptor 
SLC39A10 XM_047707 Solute carrier family 39 (zinc transporter), member 10 
SAMD3 NM_152552 Sterile alpha motif domain containing 3 
FLRT2 NM_013231 Fibronectin leucine rich transmembrane protein 2/cell adhesion 
MGC14156 NM_032906 PIGY phosphatidylinositol glycan anchor biosynthesis, class Y 
BPI NM_001725 NEDD4 binding protein 1 
LOC341511 XM_292109 Homo sapiens similar to 60S ribosomal protein L23a 
C6orf188 NM_153711 Hypothetical protein 
MXD3 NM_031300 MAX dimerization protein 3 
LGR6 NM_021636 Leucine-rich repeat-containing G protein-coupled receptor 6 
PCNA NM_002592 Proliferating cell nuclear antigen 
P162_C9 XM_096669 Homo sapiens hypothetical LOC144705 
GAD1 NM_013445 Glutamate decarboxylase 1 (brain, 67kDa) 
FLJ11331 NM_018392 C4orf21 
CMYA4 NM_173167 Unc-45 homolog B 
P181_E10 XM_372694 imilar to RIKEN cDNA C230094B15  
P188_D7 XM_374566 Homo sapiens similar to T-cell receptor beta  
a Genes show 2-fold enrichment or greater and p value <0.05. 
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Table B-2 Enriched motifs within p/CIP/CARM1 target promoters. 
Motif p-value Yes No Enrichment (Yes/No) 
V$KID3_01 0.000 0.5028 0.0000 inf 
V$ZF5_B 3.99E-41 0.2712 0.0000 inf 
V$ETF_Q6 2.77E-40 0.2655 0.0000 inf 
V$SP1_Q2_01 1.08E-24 0.1977 0.0089 22.1458 
V$PAX4_01 1.31E-22 0.1469 0.0000 inf 
V$POU3F2_02 1.96E-22 0.1695 0.0054 31.6394 
V$POU3F2_01 4.34E-22 0.2203 0.0250 8.8136 
V$OG2_01 1.44E-21 0.1751 0.0089 19.6149 
V$CDXA_02 3.52E-21 0.1921 0.0161 11.9526 
V$PAX4_02 1.91E-18 0.1412 0.0054 26.3661 
V$CETS1P54_03 2.12E-18 0.1186 0.0000 inf 
V$FOXJ2_02 8.53E-17 0.1525 0.0107 14.2376 
V$PAX4_03 1.47E-17 0.1130 0.0000 inf 
V$PLF_02 4.25E-16 0.1299 0.0071 18.1918 
V$SREBP1_01 4.49E-16 0.1243 0.0054 23.2022 
V$KROX_Q6 4.49E-16 0.1243 0.0054 23.2022 
V$TST_01 4.63E-16 0.1525 0.0161 9.4918 
V$PAX5_02 7.09E-16 0.1017 0.0000 inf 
V$WT1_Q6 7.09E-16 0.1017 0.0000 inf 
V$HOX13_01 1.25E-14 0.1412 0.0161 8.7887 
V$CART1_01 8.66E-14 0.1130 0.0071 15.8188 
V$OCT4_02 1.01E-13 0.1073 0.0054 20.0383 
V$NKX25_02 1.69E-13 0.1243 0.0125 9.9435 
V$AP4_01 1.69E-13 0.1243 0.0125 9.9435 
V$AP2_Q6 2.58E-13 0.1186 0.0107 11.0737 
V$IPF1_Q4 5.14E-13 0.1356 0.0196 6.9029 
V$GABP_B 6.07E-13 0.1017 0.0054 18.9836 
V$SRY_02 6.07E-13 0.1017 0.0054 18.9836 
V$CEBPGAMMA_Q6 8.91E-13 0.1186 0.0125 9.4915 
V$CHOP_01 7.48E-12 0.1073 0.0107 10.0191 
V$CDPCR3_01 7.48E-12 0.1073 0.0107 10.0191 
V$AP2_Q6_01 1.41E-11 0.1130 0.0143 7.9094 
V$NCX_01 1.45E-11 0.1864 0.0607 3.0708 
V$TEL2_Q6 1.22E-10 0.1017 0.0125 8.1356 
V$XVENT1_01 1.28E-10 0.1186 0.0214 5.5366 
V$MAZ_Q6 1.55E-10 0.1356 0.0321 4.2184 
V$OCT1_02 1.88E-10 0.1073 0.0161 6.6794 
V$PAX4_04 8.90E-10 0.1017 0.0161 6.3279 
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V$BRCA_01 1.11E-09 0.1073 0.0196 5.4648 
V$FAC1_01 2.42E-09 0.1243 0.0321 3.8669 
V$OCT1_03 4.90E-09 0.1017 0.0196 5.1772 
V$HNF3ALPHA_Q6 4.90E-09 0.1017 0.0196 5.1772 
V$RFX1_02 4.97E-09 0.1186 0.0304 3.9083 
V$PAX3_B 5.26E-09 0.1130 0.0268 4.2184 
V$TBX5_01 5.26E-09 0.1073 0.0232 4.6241 
V$HMGIY_Q6 1.06E-08 0.1017 0.0214 4.7457 
V$CP2_02 1.06E-08 0.1017 0.0214 4.7457 
V$VDR_Q3 1.06E-08 0.1017 0.0214 4.7457 
V$PAX6_01 1.63E-08 0.1356 0.0464 2.9204 
V$HAND1E47_01 3.49E-08 0.1638 0.0732 2.2379 
V$CEBPDELTA_Q6 8.21E-08 0.1017 0.0268 3.7966 
V$STAT1_01 8.21E-08 0.1017 0.0268 3.7966 
V$CKROX_Q2 1.19E-07 0.1412 0.0589 2.3968 
V$GATA4_Q3 1.51E-07 0.1017 0.0286 3.5594 
V$PAX8_01 4.28E-07 0.2429 0.1696 1.4321 
V$GRE_C 4.35E-07 0.1243 0.0500 2.4859 
V$AP2ALPHA_01 7.82E-07 0.1017 0.0339 2.9973 
V$CEBP_Q3 9.97E-07 0.1073 0.0393 2.7324 
V$VMYB_02 1.28E-06 0.1017 0.0357 2.8475 
V$CREB_Q4_01 1.57E-06 0.1073 0.0411 2.6136 
V$TAXCREB_02 2.06E-06 0.1017 0.0375 2.7119 
V$PAX6_Q2 3.07E-06 0.1243 0.0589 2.1092 
V$AP1_Q2_01 5.01E-06 0.1017 0.0411 2.4761 
V$RFX_Q6 5.56E-06 0.1073 0.0464 2.3120 
V$BCL6_Q3 5.92E-06 0.1130 0.0518 2.1819 
V$LRF_Q2 6.11E-06 0.1186 0.0571 2.0763 
V$PPARG_02 7.58E-06 0.1017 0.0429 2.3729 
V$PAX5_01 8.55E-06 0.1243 0.0643 1.9335 
V$PAX_Q6 1.12E-05 0.1525 0.0946 1.6118 
V$USF_Q6_01 1.13E-05 0.1017 0.0446 2.2780 
V$LEF1TCF1_Q4 1.18E-05 0.1243 0.0661 1.8812 
V$MAF_Q6_01 1.65E-05 0.1017 0.0464 2.1903 
V$PAX2_02 1.70E-05 0.1073 0.0518 2.0729 
V$MYB_Q3 3.36E-05 0.1073 0.0554 1.9391 
V$TTF1_Q6 4.63E-05 0.1073 0.0571 1.8785 
V$PPARA_01 4.65E-05 0.1299 0.0804 1.6171 
V$ER_Q6 4.75E-05 0.1017 0.0518 1.9638 
V$CACD_01 6.31E-05 0.1073 0.0589 1.8216 
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V$NKX25_Q5 6.58E-05 0.1017 0.0536 1.8983 
V$TAL1BETAE47_01 6.58E-05 0.1017 0.0536 1.8983 
V$ZIC2_01 9.01E-05 0.1017 0.0554 1.8371 
V$SPZ1_01 1.22E-04 0.1017 0.0571 1.7797 
V$CDP_02 1.63E-04 0.1017 0.0589 1.7257 
V$STAT_Q6 1.63E-04 0.1017 0.0589 1.7257 
* Cutoff conditions p < 0.001, Yes/No > 1.2 
Table B-3 Primer List. 
ChIP Validations: 
Gene Target 5’ 3’ 
pS2 GGCCATCTCTCACTATGAATCACTTCTGC GGCAGGCTCTGTTTGCTTAAAGAGCG 
CyclinA2 GCTAACTAGACGTCCCAGAGC GGGGAGAGGTAGGATTTAGG 
NFkB1 GCCTGGTACACTATAGCAGTC ATCGCCCTCTGAACTTCAAC 
WBP11 GGGCGAAGGCTAGAGT_AAGT GATTGCTTATATGGGCGGTG 
DYRK1A CCTCTTCTGCTGATTATCAGT CTGAGACATTTCTCACAACC 
IL15RA GTCTGCTCTCCGATGACTTTG CAGGACCTTACCCACGCAAG 
MAPK4 GAACTCTGCACCCTGGTTTC TTGCACTTGGGTTCCTTTTC 
TGFB1 GGTCGGGAGAAGAGGAAAAA CTGAGGGACGCCGTGTAG 
NEK4 CTTTGGCTGGAACAAATGGT CCCTAAAAACTCGCCTGCTA 
KRAS2 ATTTCCCCATGACACAATCC ACCCTGTAGCACACCCTCAC 
   
Assessing Chromatin Modifications on JAK2: 
Assay 5’ 3’ 
ChIP AAGGTGGCTGATGGGAGTC CTTTCGGCTTTTCCTTCCAC 
qChIP GGTGGCTGATGGGAGTCAGG GCTTTCGGCTTTTCCTTCCACC 
Table B-4 Antibody List. 
 Antibody Name Source Catalogue # 
p/CIP  * In House  
CARM1 CARM1 Antibody Cedarlane A300-421A 
ER ERα (HC-20) Santa Cruz Biotechnology sc-543 
JAK2 JAK2 (C-14) Santa Cruz Biotechnology sc-34479 
H3R17me2 Anti-dimethyl-Histone H3 (Arg17) (rabbit immunoaffinity purified IgG) Upstate 07-214 
H3K4me3 Mouse monoclonal to Histone H3  (tri methyl K4) AbCam ab1012 
H3R2me2 Anti-dimethyl-Histone H3 (Arg2)  (rabbit antiserum) Millipore 07-585 
H3Ac(K9, K14) Anti-acetyl-Histone H3  (rabbit polyclonal IgG) Upstate 06-599 
STAT3 Stat3 (79D7) (rabbit mAb) Cell Signaling Technology #4904 
P-STAT3 Phospho-Stat3 (Tyr705)  Cell Signaling Technology #9131 
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Appendix C: Supplementary Information for Chapter 3: Whole 
Genome analysis of CARM1 in wildtype and CARM1-knockout 
Mouse Embryonic Fibroblasts. 
 
Figure C-1 Additional characterization of CARM1 genome-wide binding 
(A) ChIP analysis validating CARM1 recruitment to indicated genomic regions, identified by 
ChIP-Seq. (B) CARM1 binding frequencies; analysis of the number of genes with 1-2, 3-5, or 6+ 
CARM1 binding events within 50kb of TSS. Correlation of CARM1 (C) binding sites or (D) 
MW-enriched regions with chromosome length. (E) Bar chart depicting the prevalence of number 
of multiple CARM1 binding events within 50kb of the TSS on each chromosome. 
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Figure C-2 Chromosomal view depicting co-occurrence of CARM1 enriched regions 
and PAX1 motifs 
 
 
 
Figure C-3 siRNA-mediated depletion of PAX1 in wildtype MEFs 
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Primers used for ChIP Validations: 
Apbb1ip F: AACGGGGAGTGGGAAAGAT 
Apbb1ip R: AAGCGGGTGGTAAACTCCAT 
Ctnnd2 F: GCCTTGCCCTAAGAGTAGCTT 
Ctnnd2 R: ACGTGTGGCCCTAGAGCTT 
Gm7120 F: GGAGCTCCTCTGCTGGAATA 
Gm7120 R: ACAGTCACACAGCCACACC 
Raet1d F: GGAGCAAGCGAAAATGATTG 
Raet1d R: CCTGAACAGGTATCAATGCAAA 
 
 
 
Primers used for Pax-1 ChIPs: 
Chr 1- Col9a1 F: AACAATTCATGCGCATTCTG 
Chr 1 - Col9a1 R: GGCAGAACTCGGACAGTCAT 
Chr4 - Mllt3 F: TCAAGCTTGTTCAGATGTGAAATTA 
Chr4 - Mllt3 R: CCCACTTTGCCAGTTTAGGA 
Chr5 - Mag2 F: GGATAGTGATTCCCCCAGAAG 
Chr5 - Mag2 R: ATGTCCATCTTGCCAAAAGC 
Chr9 - Mir101c F: GACTGTGCAATTGGGGAGTAA 
Chr9 - Mir101c R: CTGCCCAACCTAAAGTCCTG 
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